documents incorporated reference portions proxy statement filed april part iii explanatory note amendment bristolmyers squibb company 's annual report year ended december includes restated consolidated financial statements december three years period ended december company experienced substantial buildup wholesaler inventories us pharmaceuticals business several years primarily buildup primarily due sales incentives offered company wholesalers incentives generally offered towards end quarter order incentivize wholesalers purchase products amount sufficient meet company 's quarterly sales projections established company 's senior management april company disclosed substantial buildup developed subsequently undertook plan work orderly fashion wholesaler inventory levels late october based review consideration previously disclosed buildup wholesaler inventories company 's us pharmaceuticals business incentives offered certain wholesalers advice company 's independent auditors pricewaterhousecoopers llp companydetermined required restate sales earnings correct errors timing revenue recognition certain sales certain us pharmaceuticals wholesalers since time company undertaken analysis transactions incentive practices us pharmaceuticals wholesalers company determined certain incentivized transactions certain wholesalers accounted consignment model rather recognizing revenue transactions upon shipment determination involved evaluation variety criteria number complex accounting judgments result analysis company determined certain sales two largest wholesalers us pharmaceuticals business accounted consignment model based part relationship amount incentives offered wholesalers amount inventory held wholesalers following determination restate sales earnings matters described company also determined would correct certain historical accounting policies conform accounting us generally accepted accounting principles gaap certain known errors made application gaap previously recorded case company believed amount error material company 's consolidated financial statements addition part restatement process company investigated accounting practices certain areas involve significant judgments determined restate additional items respect company concluded errors made application gaap including certain revisions inappropriate accounting senior management set aggressive targets company 's businesses errors inappropriate accounting corrected restatement arose least part period unrealistic expectations consequent overestimation anticipated performance certain company 's products programs result foregoing company restated financial statements three years ended december including corresponding interim periods quarterly periods ended march june restatement affects periods prior impact restatement prior periods reflected adjustment opening retained earnings january connection audits restatement previously issued financial statements company 's consolidated financial statements year ended december company 's independent auditors pricewaterhousecoopers llp identified communicated company audit committee two material weaknesses defined standards established american institute certified public accountants relating company 's accounting public financial reporting significant matters initial recording management review oversight certain accounting matters last year company searched hired new chief financial officer outside company restaffed controller position created position chief compliance officer changed leadership pharmaceuticals group response wholesaler inventory buildup matters identified restatement adjustments direction audit committee last year senior management directed company dedicate resources take steps strengthen control processes procedures order identify rectify past accounting errors prevent recurrence circumstances resulted need restate prior period financial statements company also revised budgeting process emphasize bottomup approach contrast topdown approach company implemented review certification process annual quarterly reports securities exchange act amended well processes designed enhance monitoring wholesaler inventories addition company process expanding business risks disclosure group includes senior management including chief executive officer chief financial officer taking number additional steps designed create open environment communications flow information throughout company company continues identify implement actions improve effectiveness disclosure controls procedures internal controls including plans enhance resources training respect financial reporting disclosure responsibilities review actions audit committee independent auditors restatement previously issued financial statements reduced company 's net earnings diluted earnings per share years ended december approximately million million million respectively increased company 's net earnings diluted earnings per share six months ended june approximately million company 's accounting using consignment model certain sales two largest wholesalers us pharmaceuticals business discussed item management 's discussion analysis financial condition results operations part ii note restatement previously issued financial statements restated consolidated financial statements discloses nature restatement adjustments shows impact category restatement adjustments net sales earnings continuing operations minority interest income taxes earnings continuing operations discontinued operations net earnings related per share amounts restated annual period cumulative impact adjustments condensed statement operations condensed balance sheet restated annual period addition note restated consolidated financial statements shows effects adjustment opening retained earnings january adjustment reflects impact restatement periods prior information impact restatement years reference made item selected financial data part ii discussion company 's revenue recognition policy reference made note accounting policies restated consolidated financial statements company revised note restated consolidated financial statements present revised accounting policies certain matters included restatement notes consolidated financial statements affected restatement also revised amends restates items part items part ii item part iv original information included original amended hereby explanatory caption beginning item sets forth nature revisions item company amend annual reports quarterly reports form q periods affected restatement ended prior december financial statements related financial information contained reports longer relied upon discussion events developments subsequent december see company 's quarterly report form q quarterly period ended september filed concurrently company 's subsequent filings item businessthis item revised reflect restatement company 's business segment reorganization became effective first quarter certain developments occurring subsequent filing original respect company 's business including update information respect patents owned licensed company addition item revised incorporate certain conforming changes description bristolmyers squibb company general bristolmyers squibb company bristolmyers squibb company incorporated laws state delaware august name bristolmyers company successor new york business started bristolmyers company changed name bristolmyers squibb company result merger company divisions subsidiaries major producer distributor pharmaceuticals healthcare related products three reportable segmentspharmaceuticals nutritionals healthcare company announced planned divestiture clairol zimmer businesses accordingly operations businesses reflected discontinued operations accompanying restated consolidated financial statements november company completed sale clairol billion august company spun zimmer holdings inc taxfree distribution october company acquired dupont pharmaceuticals business dupont ei du pont de nemours company billion cash dupont primarily domestic pharmaceutical imaging product business focused research development addition november company purchased million shares imclone systems incorporated imclone per share million represented shares outstanding prior company 's commencement public tender offer imclone shares equity investment imclone part strategic agreement company imclone also includes arrangement subject additional payments company codevelop copromote investigational cancer drug erbitux transactions financed proceeds issuance billion commercial paper issuance billion mediumterm notes internal cash flows business segments reference made note segment information restated consolidated financial statements company three reportable segmentspharmaceuticals nutritionals healthcare pharmaceuticals segment pharmaceuticals segment manufactures distributes sells branded generic ethical pharmaceuticals products sold worldwide primarily wholesalers retail pharmacies hospitals medical profession company manufactures products us puerto rico fifteen foreign countries pharmaceuticals sales accounted approximately company 's restated sales respectively sales selected products product categories pharmaceuticals segment follows restated restated restated dollars millions pravachol glucophage oncology therapeutics network plavix taxol paraplatin zerit avapro monopril serzone cefzil buspar capotencapozide glucovance tequin videx glucophage xr pravachol pravastatin sodium hmg coa reductase inhibitor indicated primary hypercholesterolemia compositon matter patent expires us october patents expire expired internationally glucophage glucophage metformin oral antidiabetes agent type noninsulindependent diabetes hatch xr glucovance waxman exclusivity expired glucophage september generic metformin become available us january hatchwaxman data protection expire glucophage xr october glucovance july oncology therapeutics network specialty distributor anticancer medicines related products company otn entered agreement mckesson corporation distribution pharmaceutical products relating otn company restated previously issued financial statements account sales agreement using consignment model described fully note restatement previously issued financial statements restated consolidated financial statementsplavix clopidogrel platelet inhibitor codeveloped jointly marketed sanofisynthelabo composition matter patents us expire july november internationally discussion related litigation reference made item legal proceedings part note litigation matters restated consolidated financial statements taxol paclitaxel used treatment refractory ovarian cancer firstline treatment ovarian cancer combination cisplatin secondline treatment aidsrelated kaposi 's sarcoma treatment metastatic breast cancer failure combination chemotherapy adjuvant treatment node positive breast cancer treatment nonsmall cell lung carcinoma cisplatin data exclusivity taxol japan expire july european union september patents covering various aspects taxol extend beyond japan europe discussion related litigation reference made item legal proceedings part note litigation matters restated consolidated financial statements paraplatin carboplatin chemotherapeutic agent used treatment ovarian cancer patent expired france june expire us april zerit stavudine used treatment persons advanced human immunodeficiency virus hiv infection patent expires us june internationally avapro irbesartan angiotensin ii receptor antagonist indicated treatment hypertension codeveloped jointly marketed sanofisynthelabo composition matter patent us expires september internationally monopril fosinopril sodium secondgeneration angiotensin converting enzyme ace inhibitor onceaday dosing indicated treatment hypertension composition matter patent us expired december extended six months pediatric extension expected expire june composition matter patents expire expired internationally serzone nefazodone antidepressant treatment patent expired us march extended six months pediatric extension expected expire september patents expire expired internationally cefzil cefprozil oral cephalosporin used treatment respiratory infections sinusitis us patent expires december internationally buspar buspirone novel antianxiety agent persistent anxiety without accompanying depressive symptoms us anxiolytic use patent expired may us food drug administration fda granted company additional six months exclusivity based performance pediatric studies patents outside us expired discussion related litigation reference made item legal proceedings part note litigation matters restated consolidated financial statements capotencapozide captopril ace inhibitor patents expired us significant international markets tequin gatifloxacin advanced quinolone antiinfective patents expire us december expected patent term extension expire expired internationally january june videxvidex ec didanosine antiretroviral drug used treatment adult pediatric patients advanced hiv infection method use patent expires us august internationally patent held national institutes health company 's license patent became nonexclusive october nutritionals segment nutritionals segment manufactures distributes sells infant formulas nutritional products products generally sold wholesalers retailers promoted primarily consumers worldwide advertising company manufactures products us puerto rico five foreign countries nutritionals sales accounted company 's restated sales respectively sales selected products product categories nutritionals segment follows restated restated restated dollars millions enfamil enfalac nutramigen prosobee children 's nutritional supplements healthcare segment healthcare segment consists convatec medical imaging consumer medicines us japan healthcare sales accounted company 's restated sales company 's restated sales convatecconvatec manufactures distributes sells ostomy modern wound skin care products principal brands convatec include surfit esteem aquacel duoderm products marketed sold worldwide primarily hospitals medical profession company manufactures products us united kingdom convatec sales accounted approximately company 's sales case restated medical imaging medical imaging manufactures distributes sells cardiovascular imaging products principal brands medical imaging include cardiolite definity products marketed sold worldwide primarily hospitals medical profession company manufactures products us puerto rico medical imaging purchased part dupont acquisition completed october generated sales million fourth quarter consumer medicines consumer medicines manufactures distributes sells overthecounter health care products principal consumer health care brands include excedrin bufferin comtrex products generally sold retailers promoted primarily consumers us japan advertising products manufactured us puerto rico japan consumer medicines sales accounted company 's restated sales sources availability raw materials general bristolmyers squibb purchases principal raw materials supplies open market substantially materials obtainable number sources loss one source supply would material adverse effect company patents trademarks licenses company owns licensed number patents united states foreign countries covering products also developed many brand names trademarks products company considers overall protection patent trademark license rights material value acts protect rights infringement composition matter patent monopril expired december extended six months pediatric extension expected expire june composition matter patent serzone expired march extended six months pediatric extension expected expire september additional us patents expected expire next three years include patent cefzil december composition matter patent plavix july addition use patent paraplatin expire april hatchwaxman data protection expire glucophage xr october glucovance july videx ec october except already noted expiry dates could extended additional six months pediatric extension upon completion acceptance pediatric studies fda advance expiration competition distribution customers markets bristolmyers squibb competes generally broadbased highly competitive principal means competition used market products bristolmyers squibb include quality service price product performance pharmaceutical products products convatec promoted national international basis medical journals directly medical profession company also using directtoconsumer advertising number pharmaceutical products products bristolmyers squibb generally advertised promoted national international basis use television radio print media consumer offers window instore displays bristolmyers squibb 's products principally sold wholesale retail trade nationally internationally certain products also sold drug manufacturers hospitals medical profession sales amerisourcebergen corporation cardinal health inc cardinal mckesson corporation mckesson accounted company 's net sales restated sales cardinal accounted company 's net sales restated sales mckesson accounted company 's net sales restated company accounts certain sales pharmaceutical products cardinal mckesson using consignment model discussion company 's accounting using consignment model relationship wholesalers see note accounting policies note restatement previously issued financial statements restated consolidated financial statements item management 's discussion analysis financial condition results operations part ii research development research development essential bristolmyers squibb 's business pharmaceutical research development carried bristolmyers squibb pharmaceutical research institute major facilities princeton hopewell new brunswick new jersey wilmington delaware wallingford connecticut pharmaceutical research development also carried various facilities united states belgium canada france italy united kingdom management continues emphasize leadership innovation productivity strategies success pharmaceutical research institute bristolmyers squibb spent million million million company sponsored research development activities pharmaceutical research development spending percentage restated pharmaceutical sales compared research development spending fourth quarter related dupont imclone million regulation aspects company 's business subject degree government regulation countries operations conducted company 's policy comply fully regulatory requirements applying products operations products countries government regulation significant general trend towards stringent regulation company devotes significant time effort expense addressing extensive governmental regulatory requirements applicable business governmental regulatory actions result recall seizure products suspension revocation authority necessary production sale product civil criminal sanctionsin united states drug medical device diagnostic food industries company operates long subject regulation various federal state local agencies primarily product manufacture safety efficacy advertising labeling addition governmental bodies united states well countries expressed concern costs relating health care cases focused attention pricing drugs appropriate drug utilization government regulation areas already exists countries may expanded significantly united states countries future company unable predict extent business may affected future regulatory developments believes substantial experience dealing governmental regulatory requirements restrictions operations throughout world development new improved products enable compete effectively within environment employees bristolmyers squibb employees continuing operations approximately people december domestic foreign operations reference made note financial instruments note segment information restated consolidated financial statements international operations subject certain risks inherent conducting business abroad including possible nationalization expropriation price exchange controls limitations foreign participation local enterprises restrictive governmental actions addition changes relative value currencies take place time time effects may favorable unfavorable bristolmyers squibb 's operations currency restrictions relating repatriation earnings certain countries indicates brand names products registered trademarks owned company erbitux trademark imclone systems incorporated avapro plavix trademarks sanofisynthelabo france corp corzide delestrogen corgard florinef trademarks king pharmaceuticals inc estrace trademark galen chemicals limited viactiv trademark mcneilppc inc glucophage glucophage xr glucovance trademarks merck sante sas associate merck kgaa darmstadt germany licensed bristolmyers squibb company solage trademark galderma sa ovcon trademark warner chilcott inc sea breeze trademark shiseido company ltd abilify trademark otsuka pharmaceutical company ltd item legal proceedings item updated events developments occurring subsequent filing original addition item revised incorporate certain conforming changes various lawsuits claims proceedings pending company certain subsidiaries significant described taxol litigation company filed several lawsuits asserting number generic drug companies infringed patents covering methods administering paclitaxel filed abbreviated new drug applications seeking regulatory approval sell paclitaxel actions consolidated discovery us district court district new jersey district court company assert monetary claim defendants sought prevent defendants marketing paclitaxel manner violates patents defendants asserted infringe company 's patents patents invalid unenforceable early district court invalidated claims company 's patents issue april us court appeals federal circuit affirmed district court 's summary judgment invalidity two claims patents issue two claims relate lowdose threehour administration paclitaxel patient given specified regimen premedicants administration paclitaxel appellate court remanded two claims district court proceedings company filed additional patent infringement suit another company seeking market generic paclitaxel september one defendants received final approval us food drug administration fda abbreviated new drug application paclitaxel marketing product fda since announced additional final approvals sales additional generic products begun defendants asserted counterclaims seeking damages alleged antitrust unfair competition violations company believed patents valid filed suits counterclaims asserted believed without merit lawsuits defendants asserted counterclaims settled defendants agreeing drop claims relating paclitaxel company granting licenses certain paclitaxel patent rights since filing initial patent infringement suits six private actions filed parties alleging antitrust consumer protection similar claims relating company 's actions obtain enforce patent rights plaintiffs seek declaratory judgment damages including treble andor punitive damages allowed disgorgement injunctive relief june group state attorneys general district columbia puerto rico virgin islands brought similar claims september federal trade commission ftc initiated investigation relating paclitaxel january company announced reached agreements principle would settle substantially antitrust litigation surrounding taxol amount taxol antitrust settlements expected million amount accrued third quarter certain important terms conditions settlements remain finalized certain settlements require court approval final approval state attorneys general taxol litigation contingent upon agreements relating terms injunctive relief among provisions remaining negotiated terms incorporating certain claimants including number health insurers existing settlement framework company discussions number insurers whether ultimately join proposed settlement predicted certainty time company also reached agreement ftc staff terms consent order would resolve ftc 's investigation proposed consent order subject review approval ftc commissioners respect abovementioned proposed settlements possible time reasonably assess final outcome lawsuits orreasonably estimate possible loss range loss respect lawsuits proposed settlements become final resolve taxolrelated antitrust consumer protection similar claims company prevail final nonappealable determinations ensuing litigation impact could material buspar litigation november company obtained patent us patent ' patent relating method using buspar buspirone company timely submitted information relating ' patent fda listing fda publication commonly known orange book fda thereafter listed patent orange book delisting patent suits genericdrug manufacturers sued fda company compel delisting ' patent orange book although one district court declined order delisting ' patent another ordered company cause delisting patent orange book company complied court 's order appealed decision united states court appeals federal circuit appellate court reversed district court ordered delisting concurrently company sought enforce ' patent actions two generic drug manufacturers antitrust suits following delisting ' patent orange book number purchasers buspirone several generic drug makers filed lawsuits company alleging improperly triggered statutory marketing exclusivity plaintiffs claimed violation antitrust consumer protection similar laws attorneys general states puerto rico also filed suit company parallel allegations plaintiffs amended allegations include charges agreement company generic company improperly blocked entry generic buspirone market plaintiffs seek declaratory judgment damages including treble andor punitive damages allowed disgorgement injunctive relief multidistrict litigation mdl proceedings judicial panel mdl granted company 's motions patent antitrust cases consolidated single forum court buspirone litigations pending issued two opinions dated february first opinion court found ' patent cover uses buspirone therefore infringed second opinion court denied company 's motion dismiss federal antitrust various state law claims second opinion allows claims company proceed except federal antitrust claims damages accrued four years filing complaints government investigations ftc number state attorneys general initiated investigations concerning matters alleged antitrust suits discussed company cooperated investigations number attorneys general filed action company noted proposed settlements january company announced reached agreements principle would settle substantially antitrust litigation surrounding buspar amount buspar settlements expected million million accrued fourth quarter million accrued first quarter million accrued third quarter written settlement agreements number parties signed certain settlements require court approval number health insurers agreed proposed settlement framework whether cases ultimately settled predicted certainty time company also reached agreement ftc staff terms consent order would resolve ftc 's investigation proposed consent order subject review approval ftc commissioners respect abovementioned proposed settlements buspar antitrust litigation possible time reasonably assess final outcome lawsuits reasonably estimate possible loss range loss respect lawsuits proposed settlements become final resolve busparrelated antitrust consumer protection similar claims company prevail final nonappealable determinations ensuing litigation impact could material vanlev litigation april may june company former chairman board chief executive officer charles heimbold jr former chief scientific officer peter ringrose phd named defendants number class action lawsuits alleging violations federal securities laws regulations actions consolidated one action us district court district new jersey plaintiff claims defendants disseminated materially false misleading statements andor failed disclose material information concerning safety efficacy commercial viability product vanlev period november april may plaintiff submitted amended complaint adding allegations company present chairman board chief executive officer peter r dolan former chairman board chief executive officer charles heimbold jr former chief scientific officer peter ringrose phd disseminated materially false misleading statements andor failed disclose material information concerning safety efficacy commercial viability vanlev period april march number related class actions making essentially allegations also filed us district court southern district new york actions transferred us district court district new jersey plaintiff purports seek compensatory damages costs expenses behalf shareholders possible time reasonably assess final outcome litigation reasonably estimate possible loss range loss respect litigation company prevail final nonappealable determinations litigation impact could material plavix litigation company part owner entity plaintiff two pending patent infringement lawsuits united states district court southern district new york entitled sanofisynthelabo sanofisynthelabo inc bristolmyers squibb sanofi pharmaceuticals holding partnership v apotex inc apotex corp cv rws sanofisynthelabo sanofisynthelabo inc bristolmyers squibb sanofi pharmaceuticals holding partnership v dr reddy 's laboratories ltd dr reddy 's laboratories inc cv rws suits based us patent discloses claims among things hydrogen sulfate salt clopidogrel marketed plavix us patent discloses claims among things use clopidogrel prevent secondary ischemic event plaintiffs ' infringement position based defendants ' filing abbreviated new drug applications fda seeking approval sell generic clopidogrel prior expiration patents suit possible time reasonably assess final outcome lawsuits reasonably estimate possible loss range loss respect lawsuits patent protection plavix lost impact company 's operations could material securities mattersduring period march may company number current former officers named defendants number securities class action lawsuits alleging violations federal securities laws regulations plaintiffs variously alleged defendants disseminated materially false misleading statements failed disclose material information concerning three different matters safety efficacy commercial viability vanlev discussed company 's sales incentives certain wholesalers inventory levels wholesalers company 's investment relations imclone systems incorporated imclone imclone 's product erbitux discussed allegations concerning vanlev transferred us district court district new jersey consolidated action pending remaining actions consolidated pending us district court southern district new york allegations remaining actions cover period january april plaintiffs seek compensatory damages costs expenses october number company 's officers directors former directors named defendants shareholder derivative suit pending us district court southern district new york company nominal defendant suit alleges among things violations federal securities laws breaches contract fiduciary duty connection company 's sales incentives certain wholesalers inventory levels wholesalers investment imclone imclone 's product erbitux two similar actions pending new york state court plaintiffs seek damages costs attorneys ' fees april sec initiated inquiry wholesaler inventory issues referenced became formal investigation august december investigation expanded include certain accounting issues including issues related establishment reserves accounting certain asset sales october united states attorney 's office district new jersey announced investigation wholesaler inventory issues referenced since expanded cover subject matter sec investigation opinion management material adjustments necessary correct previously issued financial statements recorded part restatement company expect restatement described however company reasonably assess final outcome investigations time company cooperating investigations possible time reasonably assess final outcome litigations investigations reasonably estimate possible loss range loss respect litigations investigations company producing documents actively cooperating investigations investigations could result assertion criminal andor civil claims company prevail final nonappealable determinations litigations investigations impact could material erisa litigation december first quarter company others named defendants number class actions brought federal employee retirement income security act erisa cases pending us district courts southern district new york district new jersey plaintiffs allege defendants breached various fiduciary duties imposed erisa owed participants bristolmyers squibb company savings investment program program including duty disseminate material information concerning safety data company 's product vanlev company 's sales incentives certain wholesalers inventory levels wholesalers company 's investment relations imclone imclone 's product erbitux connection allegations plaintiffs assert defendants breached fiduciary duties diversify program assets monitor investment alternatives avoid conflicts interest remedy alleged fiduciary breaches cofiduciaries case pending district new jersey plaintiffs additionally allege violation defendants duty disseminate material information concerning alleged anticompetitive activities related company 's products buspar taxol pravachol plaintiffs seek recover losses caused defendants ' alleged violations erisa attorneys ' fees possible time reasonably assess final outcome matters reasonably estimate possible loss range loss respect lawsuits company prevail final nonappealable determinations matters impact could material average wholesale pricing litigation company together number pharmaceutical manufacturers defendant series state federal actions private plaintiffs brought purported class actions complaints filed attorneys general two states one county alleging manufacturers ' reporting prices certain products resulted false overstated average wholesale price awp turn improperly inflated reimbursement paid medicare beneficiaries insurers state medicaid programs medical plans others health care providers prescribed administered products federal cases many state cases including attorney general cases removed federal courts consolidated pretrial purposes transferred united states district court district massachusetts pharmaceutical industry average wholesale price litigation awp multidistrict litigation september several private plaintiffs awp multidistrict litigation filed master consolidated complaint master complaint superseded complaints preconsolidated constituent cases master complaint asserts claims federal rico statute state consumer protection fair trade statutes company defendants moved dismiss master complaint motions heard january nevada montana attorneys general moved respective cases remanded state court argument motion scheduled march company also defendant related state court proceedings new york new jersey california arizona tennessee one federal court proceeding new york commenced county suffolk new york new jersey state court proceedings currently stayed company defendants removed intend remove state court cases federal court seek transferred awp multidistrict litigation company anticipates county suffolk case also transferred plaintiffs seek damages well injunctive relief aimed manufacturer price reporting practices cases preliminary stage company unable assess outcome possible effect business profitability reasonably estimate possible loss range loss respect cases company together number pharmaceutical manufacturers also received subpoenas document requests various government agencies seeking records relating pricing marketing practices drugs covered medicare andor medicaid requests records come united states attorney 's office district massachusetts office inspector general department health human services conjunction civil division department justice several states company producing documents actively cooperating investigations could result assertion criminal andor civil claims company unable assess outcome reasonably estimate possible loss range loss respect investigations could include imposition fines penalties administrative remedies breast implant litigationthe company together subsidiary medical engineering corporation mec certain companies remains defendant number claims lawsuits alleging damages personal injuries various types resulting polyurethanecovered breast implants smoothwalled breast implants formerly manufactured mec related company vast majority claims company direct lawsuits resolved settlements trial likewise claims potential claims company registered nationwide class action settlement approved federal district court birmingham alabama revised settlement resolved revised settlement company established accruals respect breast implant product liability litigation company believes possible loss addition amounts accrued material item selected financial data fiveyear financial summary set forth item revised reflect restatement fiveyear financial summary restated restated restated restated restated millions except per share data income statement data net sales expenses cost products sold marketing selling administrative advertising product promotion research development acquired inprocess research development provision restructuring items earnings continuing operations minority interest income taxes provision income taxes minority interest net taxes earnings continuing operations earnings continuing operations per common share basic diluted dividends declared per common share financial position data december total assets longterm debt stockholders ' equity average common shares outstanding basic average common shares outstanding diluted includes gain sale businessesproduct lines taxes million million million million includes charges prescription drug pricing litigation million pending future product liability claims million taxes includes minority interest expense income unconsolidated affiliates financial position data relate company 's assets liabilities including discontinued operations years restatement adjustments affecting years set forth following table previously previously reported restated reported restated dollars millions net sales earnings continuing operations earnings continuing operations per common share basic diluted financial position data december total assets stockholders ' equity restatement adjustments affecting years adjustments respect sales returns sales rebate accruals capitalized research development payments acquisition divestiture liabilities income taxes restatement items described note restatement previously issued financial statements restated consolidated financial statements certain adjustments stockholders ' equity affecting periods prior january including adjustment dividend accrual reflected adjustment opening retained earnings january restated years information see note restatement previously issued financial statements note discontinued operations note acquisitions divestitures note restructuring items note alliances investments note litigation matters restated consolidated financial statements item management 's discussion analysis financial condition results operations management 's discussion analysis financial condition results operations set forth item revised reflect restatement company 's business segment reorganization became effective first quarter certain events occurring subsequent filing original well incorporate certain conforming changes addition company updated disclosure respect recently issued accounting standards critical accounting policies contractual obligations retirement benefits recent developments company experienced substantial buildup wholesaler inventories us pharmaceuticals business several years primarily buildup primarily due sales incentives offered company wholesalers incentives generally offered towards end quarter order incentivize wholesalers purchase products amount sufficient meet company 's quarterly sales projections established company 's senior management april company disclosed substantial buildup developed subsequently undertook plan work orderly fashion wholesaler inventory levels late october based review consideration previously disclosed buildup wholesaler inventories company 's us pharmaceuticals business incentives offered certain wholesalers advice company 's independent auditors pricewaterhousecoopers llp company determined required restate sales earnings correct errors timing revenue recognition certain sales certain us pharmaceuticals wholesalers since time company undertaken analysis transactions incentive practices us pharmaceuticals wholesalers company determined certain incentivized transactions certain wholesalers accounted consignment model rather recognizing revenue transactions upon shipment determination involved evaluation variety criteria number complex accounting judgments result analysis company determined certain sales two largest wholesalers us pharmaceuticals business accounted consignment model based part relationship amount incentives offered wholesalers amount inventory held wholesalers following determination restate sales earnings matters described company also determined would correct certain historical accounting policies conform accounting us generally accepted accounting principles gaap certain known errors made application gaap previously recorded case company believed amount error material company 's consolidated financial statements addition part restatement process company investigated accounting practices certain areas involve significant judgments determined restate additional items respect company concluded errors made application gaap including certain revisions inappropriate accounting description restatement adjustment impact adjustment company 's previously issued financial statements see note restatement previously issued financial statements restated consolidated financial statements senior management set aggressive targets company 's businesses errors inappropriate accounting corrected restatement arose least part period unrealistic expectations consequent overestimation anticipated performance certain company 's products programs result foregoing company restated financial statements three years ended december including corresponding interim periods quarterly periods ended march june restatement affects periods prior impact restatement prior periods reflected adjustment opening retained earnings january connection audits restatement previously issued financial statements company 's consolidated financial statements year ended december company 's independent auditors pricewaterhousecoopers llp identified communicated company audit committee two material weaknesses defined standards established american institute certified public accountants relating company 's accounting public financial reporting significant matters initial recording management review oversight certain accounting matters last year company searched hired new chief financial officer outside company restaffed controller position created position chief compliance officer changed leadership pharmaceuticals group response wholesaler inventory buildup matters identified restatement adjustments direction audit committee last year senior management directed company dedicate resources take steps strengthen control processes procedures order identify rectify past accounting errors prevent recurrence circumstances resulted need restate prior period financial statements company also revised budgeting process emphasize bottomup approach contrast topdown approach company implemented review certification process annual quarterly reports securities exchange act amended well processes designed enhance monitoring wholesaler inventories addition company process expanding business risks disclosure group includes senior managementincluding chief executive officer chief financial officer taking number additional steps designed create open environment communications flow information throughout company company continues identify implement actions improve effectiveness disclosure controls procedures internal controls including plans enhance resources training respect financial reporting disclosure responsibilities review actions audit committee independent auditors company 's accounting certain sales two largest wholesalers us pharmaceuticals business consignment model discussed net sales note restatement previously issued financial statements restated consolidated financial statements throughout following management 's discussion analysis financial condition results operations referenced amounts reflect balances amounts restated basis summary consistent company 's strategy become focused pharmaceutical company number transactions completed including divestiture two nonpharmaceutical businesses clairol beauty care zimmer orthopaedics results businesses reported discontinued operations excluded consolidated sales expenses years presented addition fourth quarter company acquired dupont pharmaceuticals business dupont made equity investment imclone systems incorporated imclone biotechnology company bristolmyers squibb reported billion annual restated global sales increase domestic restated sales representing worldwide restated sales increased billion international sales increased foreign exchange unfavorable impact billion sales company include sales dupont acquisition million date acquisition company 's important product lines made significant contribution company 's sales growth many experienced double digit growth restated worldwide basis year company four blockbuster products annual restated sales excess billionpravachol glucophage plavix taxol paclitaxel fact pravachol annual restated sales excess billion addition four products company product lines million annual sales including million annual sales three million annual sales case restated information us pharmaceuticals prescriber demand reference made table compares changes net sales restated basis estimated total retail mail order customers prescription growth certain company 's primary care pharmaceutical products earnings continuing operations minority interest income taxes restated decreased billion billion net earnings continuing operations restated decreased billion billion basic diluted earnings per share continuing operations restated decreased respectively respectively decline earnings company largely due billion pretax charge writeoff inprocess research development connection dupont imclone transactions net earnings total company continuing discontinued operations restated increased billion billion total company basic diluted earnings per share restated increased respectively respectively increase total company earnings driven billion aftertax gain restated sale clairol bristolmyers squibb 's financial position remains strong december company held almost billion cash time deposits marketable securities approximately billion cash time deposits marketable securities held company 's foreign subsidiaries repatriation cash us may likely require additional tax provisions reflected restated consolidated financial statements discussion matter see critical accounting policiesincome taxes cash provided operating activities reached billion restated connection dupont imclone transactions company issued billion notes billion matures billion matures bearing coupon interest rates respectively returns shareholders included dividend distributions billion stock repurchases billion dividends declared per common share increasing per share paid dividends declared per common share consistent company 's mission extend enhance human life developing highestquality products company invested billion restated research development increase restated research development spending includes million related dupont imclone research development dedicated pharmaceutical products increased compound annualized growth spending past five years continuing investment led discovery innovative new products development new indications existing products led twelve regulatory filings including vanlev hypertension aripiprazole schizophrenia plavix acute coronary syndrome addition company received seven regulatory approvals supplemental submissions including tequin shortcourse fiveday regimen composition matter patent monopril expired december extended six months pediatric extension expected expire june composition matter patent serzone expired march extended six months pediatric extension expected expire september additional us patents expected expire next three years include patent cefzil december composition matter patent plavix july addition use patent paraplatin expire april hatchwaxman data protection expire glucophage xr october glucovance july videx ec october expiry dates could extended additional six months pediatric extension upon completion acceptance pediatric studies us food drug administration fda advance expiration october company acquired dupont pharmaceuticals business e du pont de nemours company billion company also announced collaboration agreement exelixis inc create new generation cancer drugs selectively destroy cancers harbor defects tumor suppressed gene pathways september company entered commercial agreement imclone codevelop copromote investigational cancer drug erbitux commercial agreement company required pay imclone aggregate billion upon achievement three milestones million paid million payment charged earnings remaining million recorded equity investment november company also purchased million shares imclone per share million represented approximately imclone shares outstanding prior commencement public tender offeron december imclone announced fda refused accept filing biologics license application bla submitted imclone erbitux bla submitted gain marketing approval treat irinotecanrefractory colorectal carcinoma january subcommittee oversight investigations house energy commerce committee announced investigating questions conduct imclone development erbitux january imclone announced received informal inquiry securities exchange commission well inquiries department justice aforementioned subcommittee company cooperating investigations march agreement imclone revised reduce total payments million billion revised agreement company agreed pay imclone million march million march aggregate million upon achievement two milestones also revised agreement company agreed pay imclone distribution fee based flat rate product revenues north america discussion company 's accounting equity investment imclone payments revised agreement imclone see note alliances investments restated consolidated financial statements described note restatement previously issued financial statements unaudited consolidated financial statements included company 's quarterly report form q quarterly period ended september filed concurrently company determined million payable march recognized march accordingly company corrected error restating first quarter acquired inprocess research development charge expense million million payment recorded remainder payment additional equity investment eliminate income statement effect portion payment company economic claim equity investment imclone carrying value company 's approximately equity investment imclone million december pershare basis carrying value company 's imclone investment closing market value imclone shares december respectively third quarter company recorded pretax charge earnings million temporary decline market value imclone fair value equity investment imclone used determine charge based market value imclone shares september net sales sales restated increased billion including sales million related dupont acquisition completed october domestic sales restated increased international sales increased foreign exchange unfavorably impacted sales decreased foreign exchange unfavorably impacted sales sales growth resulted increase due volume increase due changes selling prices decrease due foreign exchange rate fluctuations sales increased billion increase reflecting increase due volume increase due changes selling prices decrease due foreign exchange rate fluctuations sales increased billion result increase due volume increase due changes selling prices decrease due foreign exchange rate fluctuations general business company seasonal information us pharmaceuticals prescriber demand reference made table compares changes net sales restated basis estimated total retail mail order customers prescription growth certain company 's primary care pharmaceutical products significant portion company 's sales made wholesalers company experienced substantial buildup wholesaler inventories us pharmaceuticals business several years primarily buildup primarily due sales incentives offered company wholesalers including discounts buyins anticipation price increases extended payment terms certain us pharmaceuticals wholesalers incentives generally offered towards end quarter order incentivize wholesalers purchase products amount sufficient meet company 's quarterly sales projections established company 's senior management timing company 's recognition revenue sales wholesalers differs wholesaler period historically company recognized revenue sales upon shipment product customers gaap revenue recognized substantially risks rewards ownership transferred case sales made wholesalers result incentives excess wholesaler 's ordinary course business inventory level time understanding agreement course dealing consistent business practice company would extend incentives based levels excess inventory connection future purchases time incentives would cover substantially vary directly wholesaler 's cost carrying inventory excess wholesaler 's ordinary course business inventory level substantially risks rewards ownership transfer upon shipment accordingly sales accounted using consignment model determination sales wholesaler meet foregoing criteria involves evaluation variety factors number complex judgments consignment model company recognize revenue upon shipment product rather upon shipment product company invoices wholesaler records deferred revenue gross invoice sales price classifies inventory held wholesalers consignment inventory company 's cost inventory company recognizes revenue net discounts rebates estimated sales allowances accruals returns consignment inventory longer subject incentive arrangements later inventory sold wholesalers ' customers firstin firstout fifo basis additional discussion company 's revenue recognition policy see note accounting policies restated consolidated financial statements company restated previously issued financial statements correct timing revenue recognition certain previously recognized us pharmaceuticals sales cardinal health inc cardinal mckesson corporation mckesson two largest wholesalers company 's us pharmaceuticals business based application criteria described recorded error time shipment accounted using consignment model company determined shipments product cardinal shipments product mckesson met consignment model criteria set forth july july respectively case continuing end period thereafter accordingly consignment model required applied shipments prior respective periods company recognized revenue respect sales cardinal mckesson upon shipment product although company generally views approximately one month supply desirable level wholesaler inventory goingforward basis level wholesaler inventory representative industry average applying consignment model sales cardinal mckesson company defined inventory excess wholesaler 's ordinary course business inventory level inventory two weeks three weeks supply respectively based levels inventory cardinal mckesson required used basis negotiation incentives granted additional discussion application consignment model sales cardinal mckesson see note restatement previouslyissued financial statements restated consolidated financial statements result restatement adjustment net sales reduced million million million respectively corresponding reduction earnings continuing operations minority interest income taxes million million million respectively separately discussion march company entered distribution agreement mckesson provision warehousing order fulfillment services company 's oncology therapeutics network otn specialty distributor anticancer medicines related products prior restatement company recorded error sales agreement upon shipment product mckesson company restated previously issued financial statements account sales using consignment model described fully note restatement previously issued financial statements restated consolidated financial statements resulting reduction net sales earnings continuing operations minority interest income taxes million million respectively december company 's aggregate cost pharmaceutical products held cardinal respect mckesson accounted using consignment model accordingly reflected consignment inventory company 's consolidated balance sheet approximately million million million respectively approximately million december related otn deferred revenue recorded gross invoice sales price related inventory pharmaceutical products accounted using consignment model approximately million million million december respectively approximately million december related otn result restatement application consignment model approximately million sales calculated net customary early pay cash discounts reversed period approximately million expected recognized approximately million projected recognized sales cardinal mckesson represent approximately us pharmaceuticals net sales respectively restated basis company determined although sales incentives offered wholesalers buildup inventories wholesalers consignment model criteria discussed met accordingly company recognized revenue products shipped wholesalers company estimates inventory pharmaceutical products held us pharmaceuticals wholesalers excess approximately one month supply case company 's exclusive products approximately one half months supply case plavix avapro marketed company 's alliance sanofisynthelabo approximately two months supply case company 's nonexclusive products range approximately million million december company 's estimate based projected prescription demandbased sales products well company 's analysis thirdparty information including information obtained certain wholesalers respect inventory levels sellthrough customers thirdparty market research data company 's internal information company 's estimate subject inherent limitations estimates rely thirdparty data certain thirdparty information form estimates reflects limitations april company disclosed substantial buildup wholesaler inventories us pharmaceuticals business developed subsequently undertook plan work orderly fashion wholesaler inventory levels facilitate orderly workdown company 's plan included continuing offer sales incentives reduced levels certain wholesalers respect mckesson cardinal company entered agreements orderly workdown provide wholesalers make specified levels purchases company offer specified levels incentives workdown period company expects orderly workdown inventories pharmaceutical products held us pharmaceuticals wholesalers substantially completed end company also expects consignment model criteria longer met respect company 's us pharmaceuticals sales cardinal mckesson abovementioned sales related otn end december company 's aggregate cost pharmaceutical products held cardinal mckesson accounted using consignment model accordingly reflected consignment inventory company 's consolidated balance sheet approximately million december deferred revenue recorded gross invoice sales price related inventory approximately million including approximately million related otn company estimates based data noted inventory pharmaceutical products held us pharmaceuticals wholesalers excess approximately one month supply case company 's exclusive products approximately one half months supply case plavix avapro marketed company 's alliance sanofisynthelabo approximately two months supply case company 's non exclusive products range approximately million level supply million excess level supply december estimate subject inherent limitations noted company expects account certain pharmaceutical sales relating otn using consignment model abovementioned agreement mckesson expires company 's financial results prior period quarterly comparisons affected buildup orderly workdown wholesaler inventories well application consignment model certain sales certain wholesalers addition respect sales accounted using consignment model company 's financial results prior period quarterly comparisons affected fluctuations buying patterns wholesalers including effect incentives offered corresponding changes inventory levels maintained wholesalers wholesaler buying patterns wholesaler inventory levels may reflect underlying prescriber demand information us pharmaceuticals prescriber demand reference made table compares changes net sales restated basis estimated total retail mail order customers prescription growth certain company 's primary care pharmaceutical products company expects consignment model longer applied respect sales cardinal mckesson buying patterns fluctuations inventory levels wholesalers effect company 's financial results prior period quarterly comparisons earnings earnings continuing operations minority interest income taxes decreased million million case restated earnings continuing operations decreased million million case restated basic earnings per share decreased diluted earnings per share decreased case restated earnings continuing operations minority interest income taxes million increase earnings continuing operations million increase case restated basic earnings per share diluted earnings per share increased respectively case restated years ended december company recorded several significant items affected comparability results periods presented herein set forth following table discussion items see note acquisitions divestitures note restructuring items note alliances investments restated consolidated financial statements restated restated restated dollars millions inprocess research development charge restructuring items gain sales businessesproduct lines income taxes items million includes million inventory writedowns classified cost products sold million writeoff receivables reduction net sales million includes million cost products sold company also incurred million costs related dupont acquisition million included cost goods sold gross margins respectively gross margins adversely impacted generic competition change product mix lesser extent wholesaler sales incentives effective income tax rate earnings continuing operations restated basis compared negative effective income tax rate due lower pretax income us primarily result writeoff acquired inprocess research development restructuring charges items three months ended september company recognized income tax benefit million due settlement certain tax matters existing december determination company expected settlement ongoing tax litigation expenses continuing operations total cost expenses percentage sales case restated cost products sold percentage sales increased case restated principally due increased sales lower margin products otn decline highermargin taxol buspar sales lesser extent increase wholesaler sales incentives cost products sold percentage sales declined compared case restated principally due favorable manufacturing variances advertising promotion expenses decreased prior year million primarily due lower spending taxol buspar advertising promotion expenses increased million percentage sales restated advertising promotion expenses decreased expenses remained level marketing selling administrative expenses percentage sales decreased case restated decrease resulted continued improvement costefficiencies company 's investment research development totaled million increase percentage sales increased compared case restated spending level reflects company 's commitment research broad range therapeutic areas clinical development new products research development spending dedicated pharmaceutical products increased pharmaceuticals sales restated compared respectively acquired inprocess research development includes million writeoff related dupont imclone transactions addition inprocess research development years includes licensing payments related products yet approved marketing alternative future use million million million respectively charge primarily relates payment otsuka pharmaceutical co ltd million abilify restructuring programs implemented downsize realign streamline operations order increase productivity reduce operating expenses rationalize company 's manufacturing network research facilities program approximately employees terminated including sales force manufacturing administration research personnel addition contract sales force terminated company also exited nutritional business eastern europe pharmaceutical production facility us research facility france result actions company expects annual benefit earnings continuing operations minority interest income taxes approximately million future years actions expected substantially complete early restructuring programs implemented downsize realign streamline operations order increase productivity reduce operating expenses rationalize company 's manufacturing network research facilities program approximately employees terminated including sales force manufacturing administration research personnel addition company also exited production facility us certain international operations convatec research facility japan result actions company expects annual benefit earnings continuing operations minority interest income taxes approximately million future years actions substantially complete additional information restructuring see note restructuring items restated consolidated financial statementsin company recognized gains sales businessesproduct lines million million million respectively described note acquisitions divestitures restated consolidated financial statements company divested corzide delestrogen florinef three pharmaceutical products licensing rights corgard us estrace tablets apothecon commodity business viactiv solage product lines company completed sale three pharmaceutical productsestrace cream ovcon ovcon well sea breeze brand japan company completed sale laboratori guieu spa italianbased gynecologic pediatric dermatologic products business also company acquired calctose nutritional milk modifier product mexico business segments company operates three reportable operating segmentspharmaceuticals nutritionals healthcare pharmaceuticals pharmaceuticals sales company 's largest segment total company 's sales increased million restated sales growth resulted increase due volume decrease due effect foreign exchange rate fluctuations increase result changes selling prices pharmaceuticals sales increased restated driven increase due volume increase due changes selling prices decrease due effect foreign exchange rate fluctuations us pharmaceuticals sales increased million us pharmaceuticals sales increased million case restated increases reflect favorable impact previously disclosed buildup wholesaler inventories company 's us pharmaceuticals business impact restatement application consignment model certain sales two largest wholesalers us pharmaceuticals business additional information restatement application consignment model see note restatement previously issued financial statements restated consolidated financial statements key pharmaceutical products sales restated include following sales pravachol cholesterollowering agent company 's largestselling product increased million restated domestic sales increased million international sales increased foreign exchange negative impact million case restated december fda approved milligram version pravachol glucophage franchise sales increased million restated glucophage leading branded oral medication treatment noninsulin dependent type diabetes saw sales increase million restated company expects sales glucophage decline significantly generic metformin became available us january glucovance new oral combination drug glucophage extended release tablets sales million million respectively restated sales plavix platelet aggregation inhibitor increased million restated driven part positive results cure study clopidogrel unstable angina prevent recurrent ischemic events published new england journal medicine august sales avapro angiotensin ii receptor blocker treatment hypertension increased million restated avapro plavix cardiovascular products launched alliance bristolmyers squibb sanofisynthelabo sales taxol company 's leading anticancer agent decreased million restated international sales increased foreign exchange negative impact million restated led strong sales japan france domestic sales decreased million restated due generic competition taxol sales increased million restated sales paraplatin used combination therapy treatment ovarian cancer decreased million increased million case restated sales monopril secondgeneration angiotensin converting enzyme ace inhibitor increased million decreased million case restated sales serzone novel treatment depression increased million decreased million case restated sales buspar antianxiety agent decreased million due generic competition increased million case restated sales tequin quinolone antibiotic increased million million restated november fda approved tequin short course fiveday regimen treatment acute bacterial exacerbation chronic bronchitis sales videx antiretroviral agent increased million restated due increased sales videx ec entericcoated beadlets launched videx sales increased million restated sales otn specialty distributor anticancer medicines related products increased million million case restated following table sets forth comparison reported net sales changes restated basis estimated total retail mail order customers prescription growth certain company 's us primary care pharmaceutical products estimated prescription growth amounts based thirdparty data significant portion company 's domestic pharmaceutical sales made wholesalers change reported net sales exceeds prescription growth change net sales may reflect underlying prescriber demand change change total change change total change change total net sales prescriptions net sales prescriptions net sales prescriptionspravachol glucophage plavix avapro monopril serzone cefzil buspar excess earnings minority interest income taxes restated decreased million million result writeoff million acquired inprocess research development related dupont imclone transactions decline taxol buspar sales resulting generic competition earnings minority interest income taxes restated increased million million result increases sales prices manufacturing efficiencies nutritionals nutritionals sales million restated comparable prior year level reflecting decrease due volume increase due pricing decrease due foreign exchange mead johnson continues leader us infant formula markets total infant formula sales restated increased foreign exchange favorable impact million sales enfamil company 's largest selling infant formula increased million worldwide restated nutritionals sales million restated comparable prior year level earnings minority interest income taxes restated nutritionals segment increased million million case restated primarily due copromotion income cefzil pharmaceuticals segment lower promotion spending viactiv earnings minority interest income taxes restated decreased million million due lower sales nonwic formula healthcare healthcare segment includes convatec medical imaging businesses well consumer medicines us japan sales healthcare segment restated increased million including sales million medical imaging acquired october part dupont acquisition healthcare sales increase result increase due volume decrease due effect foreign exchange changes pricing healthcare segment sales restated declined million million primarily due lower ostomy sales healthcare sales business follows change restated restated restated dollars millions convatec consumer medicines medical imaging na na total healthcare products earnings minority interest income taxes restated increased million million primarily due inclusion medical imaging business purchased october part dupont acquisition earnings minority interest income taxes restated increased million million discontinued operations described note discontinued operations restated consolidated financial statements fourth quarter company completed sale clairol resulted pretax gain billion billion taxes restated gain included net gain disposal discontinued operations also company spun zimmer holdings inc taxfree transaction resulting common stock dividend million restated representing net book value date spinoff company completed sale matrix essentials inc affiliate clairol resulting pretax gain million million tax restated gain included net gain disposal discontinued operations also company recorded restructuring charges discontinued operations million taxes connection workforce reductions related discontinued operations net earnings discontinued operations includes earnings date divestiture decreased million million million geographic areas bristolmyers squibb products available virtually every country world company 's largest markets us france japan germany italy canada sales us increased restated products strong growth included glucophage plavix pravachol tequin avaprotaxol buspar sales declined due generic competition sales restated us increased primarily due growth glucophage plavix buspar paraplatin avapro information us pharmaceuticals prescriber demand reference made table compares changes net sales restated basis estimated total retail mail order customers prescription growth certain company 's primary care pharmaceutical products sales europe mideast africa increased restated including negative effect foreign exchange result strong growth pravachol taxol france italy sales europe mideast africa decreased restated including negative effect foreign exchange pravachol taxol avapro plavix france italy spain experienced strong growth increases partially offset decrease capoten sales due generic competition sales western hemisphere countries decreased restated including negative effect foreign exchange unfavorable impact foreign exchange felt primarily brazil underlying sales growth driven primarily increased sales mexico sales western hemisphere countries increased restated including negative effect foreign exchange increase primarily result growth canada due increased sales avapro enfamil mexico due growth enfamil calctose sales pacific region decreased restated foreign exchange negative impact sales unfavorable impact foreign exchange felt primarily japan products strong growth included taxol paraplatin japan nutritional products philippines thailand china pacific region sales increased including positive effect foreign exchange result increases bufferin taxol paraplatin financial instruments company exposed market risk due changes currency exchange rates interest rates reduce risk company enters certain derivative financial instruments available costeffective basis hedge underlying economic exposure instruments managed consolidated basis efficiently net exposures thus take advantage natural offsets derivative financial instruments used trading purposes gains losses hedging transactions offset gains losses underlying exposures hedged foreign exchange option contracts forward contracts used hedge anticipated transactions company 's primary foreign currency exposures relation us dollar japanese yen euro mexican peso canadian dollar table summarizes company 's outstanding foreign exchange contracts december fair value foreign exchange option contracts estimated using blackscholes model based yearend currency rates fair value foreign exchange forward contracts based yearend forward currency rates fair value option contracts forward contracts viewed relation fair value underlying hedged transactions overall reduction exposure adverse fluctuations foreign currency exchange rates weighted average notional strike price amount fair value maturity dollars millions except currency rates foreign exchange forwards euro mexican peso japanese yen british pound taiwan dollar thai baht brazilian real hong kong dollar argentine peso total forwards foreign exchange options japanese yen canadian dollar australian dollar total options total contracts december company held righttosell option contracts aggregate notional amount fair value million million respectively contracts primarily related option contracts right sell euros mexican pesos brazilian reals contracts december primarily included option contracts right buy japanese yen us dollars aggregate notional amount fair value million primarily included option contracts right buy japanese yen us dollars aggregate notional amount fair value million million respectively company maintains cash cash equivalents time deposits marketable securities various financial institutions financial institutions located primarily us europe company policy designed limit exposure one financial institution contractual obligations payments due period total dollars millions shortterm borrowings longterm debt operating leases total discussion contractual obligations reference made note shortterm borrowings longterm debt note financial instruments note leases restated consolidated financial statements march company imclone revised agreement reducing total payment million billion pursuant agreement company paid imclone million million million pay aggregate million upon achievement two milestones discussion company 's agreement imclone see note alliances investments restated consolidated financial statements recently issued accounting standards january financial accounting standards board fasb issued interpretation consolidation variable interest entities fin fin requires variable interest entity consolidated company company subject majority risk loss variable interest entity 's activities entitled receive majority entity 's residual returns fin also requires disclosures variable interest entities company required consolidate significant variable interest consolidation requirements fin apply immediately variable interest entities created january existing entities first fiscal year interim period beginning june certain disclosure requirements apply financial statements issued january regardless variable interest entity established company process assessing impact pronouncement consolidated financial statements based preliminary analysis impact fin company believes reasonably possible imclone meet criteria considered variable interest entity relation company accordingly company included required transitional disclosures fin note alliances investments restated consolidated financial statements december fasb issued sfas accounting stockbased compensationtransition disclosure sfas amends sfas accounting stockbased compensation provide alternative methods transition voluntary change fair value based method accounting stockbased employee compensation addition sfas amends disclosure requirements sfas require prominent disclosures annual interim financial statements method accounting stock based employee compensation effect method used reported results provisions sfas effective financial statements fiscal years interim periods ending december sfas material impact company 's consolidated financial statements adoption standard require company change company plan change fair value based method accounting stockbased compensation november fasb issued interpretation guarantor 's accounting disclosure requirements guarantees including indirect guarantees indebtedness others fin fin requires guarantor recognize liability inception guarantee fair value obligation undertaken issuing guarantee include detailed disclosure respect guarantees types contracts company enters meet scope interpretation financial performance standby letters credit behalf whollyowned subsidiaries fin effective guarantees issued modified december initial adoption accounting pronouncement material effect company 's consolidated financial statements june fasb issued sfas accounting exit disposal activities effective exit disposal activities initiated december sfas addresses issues regarding recognition measurement reporting costs associated exit andor disposal activities including restructuring activities currently accounted pursuant guidance emerging issues task force eitf set forth eitf issue liability recognition certain employee termination benefits costs exit activity including certain costs incurred restructuring sec set forth staff accounting bulletin restructuring impairment charges initial adoption accounting standard material effect company 's consolidated financial statements april fasb issued sfas superseded sfas requirement aggregate gains losses extinguishment debt classify material extraordinary item net related income tax effect result criteria accounting principles board opinion used classify gains losses sfas also amends sfas require certain lease modifications economic effects similar sale leaseback transactions accounted manner saleleaseback transactions part restatement previously issued financial statements company adopted eitf issue accounting consideration given vendor customer including reseller vendor 's products january reflecting cost certain vendor considerations eg cooperative advertising payments shelving allowances manufacturers coupons reductions revenue instead advertising product promotion expenses effect eitf material company effective january company adopted provisions sfas accounting impairment disposal longlived assets statement supersedes sfas accounting impairment longlived assets longlived assets disposed accounting reporting provisions apb opinion reporting results operationsreporting effects disposal segment business extraordinary unusual infrequently occurring events transactions disposal segment business sfas addresses accounting use determining impairment longlived assets appropriate methodology recording impairment loss initial adoption statement materialimpact consolidated financial statements company june fasb issued sfas goodwill intangible assets effective fiscal years beginning december company adopted sfas january within certain provisions applied earlier upon acquisition goodwill acquired intangible assets acquired june sfas addresses initial recognition measurement intangible assets acquired business combination recognition measurement goodwill intangible assets subsequent acquisition new rules goodwill indefinitelived intangible assets longer amortized subject annual impairment tests intangible assets continue amortized useful lives accordance sfas goodwill indefinitelived intangible assets tested impairment upon adoption standard annually thereafter sfas requires goodwill tested impairment using twostep process first step identify potential impairment second step measures amount impairment loss sfas requires indefinitelived intangible assets tested impairment using onestep process consists comparison fair value carrying value intangible asset goodwill deemed impaired carrying amount reporting unit 's goodwill exceeds estimated fair value intangible assets deemed impaired net book value exceeds estimated fair value goodwill arising business acquisitions prior july amortized straightline basis periods ranging years goodwill longer amortized effective goodwill associated dupont acquisition future business combinations amortized instead reviewed impairment least annually application nonamortization provisions material effect company 's financial statements addition june fasb issued sfas accounting asset retirement obligations sfas fair value liability asset retirement obligation must recognized period incurred reasonable estimate fair value made associated asset retirement costs capitalized part carrying amount longlived asset provisions sfas effective financial statements fiscal years beginning june initial adoption standard expected material impact company 's consolidated financial statements retirement benefits plan description company certain subsidiaries defined benefit pension plans defined contribution plans regular fulltime employees principal defined benefit pension plan bristolmyers squibb retirement income plan principal defined contribution plan bristolmyers squibb savings investment program approximately total company defined benefit pension plan assets liabilities held us plans assets us plans held single trust common asset allocation unless specified otherwise references section total company plans us plans together international plans benefits company 's defined benefit pension plans based primarily years credited service participants ' compensation assets company 's defined benefit plans consist primarily equity fixedincome securities december fair market value plan assets company 's defined benefit plans million us plans assets allocated equity securities fixed income securities real estate investments december fair market value plan assets company 's defined benefit plans million us plans assets allocated equity securities fixed income securities real estate investments bristolmyers squibb common stock represented less assets us plans end company provides comprehensive medical group life benefits substantially us retirees elect participate company 's comprehensive medical group life plans asset allocation postretirement plans identical asset allocation described us defined benefit pension plans accrual accounting significant assumptions consistent gaap requirements set forth sfas employers ' accounting pensions company accounts pension benefits using accrual method recognizing pension expense payment benefits retirees accrual method accounting pension benefits necessarily requires actuarial assumptions concerning future events determine amount timing benefit payments company 's key assumptions used calculating cost pension benefits discount rate rate compensation increase expected longterm rate return plan assets company consultation actuaries evaluates key actuarial assumptions assumptions used calculating cost pension benefits retirement turnover mortality rates based expectations actual experience appropriate determines assumptions december year calculate liability information date pension expense following year depending assumptions used pension expense could vary within range outcomes material effect reported earnings addition assumptions materially affect accumulated benefit obligations future cash funding actual results given year may differ estimated economic factors assumed discount rate used company determining future pension obligations us plans based indices aa aaarated corporate bonds indices high quality corporate bonds selected reflect weightedaverage remaining period benefit payments assumed rate compensation increase used company determining future pension obligations reflects estimate change actual future compensation levels due general price levels productivity seniority factors net pension expense company 's defined benefit pension plans included earnings minority interest income taxes million including million us curtailmentsettlement loss us plans pension expense determined using assumed discount rate assumed rate compensation increase accumulated benefit obligation december us plans determined using assumed discount rate assumed discount rate used determining us plans pension expense reduced expense would increased approximately million assumed rate compensation increase used determining us plans pension expense reduced expense would decreased byapproximately million assumed discount rate used determining accumulated benefit obligation us plans december reduced accumulated benefit obligation would increased million determining expected longterm rate return plan assets company evaluates allocation assets expected returns various asset classes company evaluates shortterm volatility context longterm nature pension commitments us plans pension expense determined using expected longterm rate return plan assets expected longterm rate return plan assets used determining us plans pension expense reduced expense would increased million actual rates return earned us plan assets last ten years follows year return year return actual rate return earned us plans assets discussed accounting principles provide differences expected actual returns recognized average future service employees december company lowered assumed discount rate reflect decline yields high quality corporate bonds assumed rate compensation increase reflect expectations lower inflation future consistent reduction assumed discount rate reduction assumed discount rate increased present value future benefit obligations accordingly effect increasing us plans pension expense contrast reduction assumed rate compensation increase decreased present value benefit obligations accordingly effect decreasing us plans pension expense net pension expense company 's defined benefit pension plans included earnings minority interest income taxes expected million december company lowered assumed discount rate us plans assumed rate compensation increase us plans aggregate revisions effect increasing present value future benefit obligations accordingly effect increasing pension expense addition company revised based change expectations future terminations retirements retirement turnover assumptions revision effect decreasing present value future benefit obligations accordingly effect decreasing pension expense course last several years global equity markets experienced negative returns negative equity market returns compounded market decline sp declined company evaluates market conditions determining expected longterm rate return plan assets company determined reduce expected rate return us plans assets december reduction expected result higher pension expense approximately million company expects net pension expense defined benefit pension plans included earnings minority interest income taxes approximately million higher reflecting among things decreases assumed discount rate expected longterm rate return outlined decrease value assets company 's defined benefit pension plans company used assumed discount rates expected longterm rates return plan assets calculating cost postretirement benefits calculating cost pension benefits delayed recognition actuarial gains losses december unrecognized net actuarial losses company 's defined benefit plans totaled million million respectively based fair market value plan assets compared unrecognized net actuarial gain million december unrecognized net actuarial losses reflect decline fair market value plan assets reduction weightedaverage discount rate sfas provides delayed recognition actuarial gains losses including amounts arising changes estimated plan benefit obligations due changes assumed discount rate differences actual expected returns plan assets assumption changes sfas requires unrecognized net actuarial gain loss determined based marketrelated value plan assets differs fair market value calculated value recognizes changes fair value systematic rational manner five years amortized pension income expense year extent unrecognized net actuarial gain loss exceeds greater projected benefit obligation marketrelated value plan assets beginning year net gains losses recognized pension income expense prospectively period approximates average remaining service period active employees expected receive benefits plans approximately years extent offset losses gains subsequent years december unrecognized net actuarial gain determined based marketrelated value plan assets million amount exceed greater projected benefit obligation marketrelated value plan assets accordingly required amortized pension income december unrecognized net actuarial loss determined based marketrelated value plan assets million amount exceed greater projected benefit obligation marketrelated value plan assets accordingly required amortized pension expense december unrecognized net actuarial loss determined based marketrelated value plan assets million amount exceeded greater projected benefit obligation marketrelated value plan assets million unless offset future unrecognized gains higher discount rates higher expected returns plan assets amortization million amount expected increase pension expense following nine years approximately million per yearin event fair market value assets particular pension plan less accumulated benefit obligation plan yearend gaap may require additional minimum liability circumstances reduction stockholders ' equity establishment intangible asset december fair market value company 's defined benefit pension plans assets million related accumulated benefit obligation million december fair market value company 's defined benefit pension plans assets decreased million related accumulated benefit obligation increased million company recognized additional minimum liability approximately million million december company also recognized additional minimum liability million december offset creation million intangible asset million reduction stockholders ' equity plan funding company 's funding policy defined benefit plans contribute amounts provide current service fund past service liability company contributed defined benefit plans million million million respectively recent decline global equity markets resulted decrease value assets company 's pension plans decline expected adversely affect company 's related accounting results future periods higher pension expense increased cash funding requirements company contributed defined benefit plans million including contribution million fourth quarter company 's contribution defined contribution plans based employee contributions level company match company contributed principal defined contribution plan million million million respectively company contributed principal defined contribution plan million critical accounting policies company prepares financial statements accordance gaap preparation financial statements conformity gaap requires use estimates assumptions affect reported amounts assets liabilities including disclosure contingent assets contingent liabilities date financial statements reported amounts revenue expenses reporting period company 's critical accounting policies important company 's financial condition results operations require difficult subjective complex judgments part management application often result need make estimates effect matters inherently uncertain uncertainty factors surrounding estimates judgments used preparation consolidated financial statements actual results may vary estimates company believes following represent critical accounting policies summary company 's significant accounting policies including critical accounting policies discussed see note accounting policies restated consolidated financial statements management company 's independent accountants discussed company 's critical accounting policies audit committee board directors revenue recognition company 's accounting policy revenue recognition substantial impact reported results relies certain estimates require difficult subjective complex judgments part management company recognizes revenue sales upon shipment product customers except case certain transactions us pharmaceuticals wholesalers accounted using consignment model gaap revenue recognized substantially risks rewards ownership transferred case sales made wholesalers result incentives excess wholesaler 's ordinary course business inventory level time understanding agreement course dealing consistent business practice company would extend incentives based levels excess inventory connection future purchases time incentives would cover substantially vary directly wholesaler 's cost carrying inventory excess wholesaler 's ordinary course business inventory level substantially risks rewards ownership transfer upon shipment accordingly sales accounted using consignment model determination sales wholesaler meet foregoing criteria involves evaluation variety factors number complex judgments consignment model company recognize revenue upon shipment product rather upon shipment product company invoices wholesaler records deferred revenue gross invoice sales price classifies inventory held wholesalers consignment inventory company 's cost inventory company recognizes revenue net discounts rebates estimated sales allowances accruals returns consignment inventory longer subject incentive arrangements later inventory sold wholesalers ' customers firstin firstout fifo basis acquired inprocess research development fair value inprocess research development acquired business combination acquired iprd determined independent appraisal based present value research project 's projected cash flows utilizing income approach consistent aicpa practice aid assets acquired business combinations used research development activities focus software electronic devices pharmaceutical industries future cash flows predominately based net income forecast project consistent historical pricing margins expense levels similar products revenues estimated based relevant market size growth factors expected industry trends individual project life cycles life research project 's underlying patent determining fair value research project expected revenues first adjusted technical risk completion resulting cash flows discounted rate approximating company 's weighted average cost capital impairment longlived assets company assesses carrying value goodwill identifiable intangible assets longlived assets least annually whenever events changes circumstances indicate carrying amount underlying asset may recoverable circumstances may include change company 's use underlying asset underperformance relative expected projected results company assesses recoverability future operations using undiscounted cash flows impairments recorded amount present value future cash flows less carrying value assets estimates future cash flows based reasonable supportable assumptions projections require management 's judgement changes key assumptions company 's businesses prospects changes market condition could result impairment charge equity investments company reviews equity investments impairment based determination whether decline market value investment company'scarrying value temporary making determination company considers accounting principles board opinion equity method accounting investments common stock sets forth factors evaluated determining whether loss value recognized including company 's ability hold investment market price market price fluctuations investment 's publicly traded shares inability investee sustain earnings capacity would justify carrying amount investment company 's investment imclone subject accounting retirement benefits company 's pension plans postretirement benefit plans accounted using actuarial valuations required sfas employers ' accounting pensions sfas employers ' accounting postretirement benefits pensions company considers accounting retirement plans critical management required make significant subjective judgments number actuarial assumptions including discount rates salary growth longterm return plan assets retirement turnover health care cost trends rates mortality rates depending assumptions estimates used pension postretirement benefit expense could vary within range outcomes material effect reported earnings addition assumptions materially affect accumulated benefit obligations future cash funding detailed discussion company 's retirement benefits see retirement benefits note retirement plans note postretirement benefit plans pensions restated consolidated financial statements restructuring downsize streamline operations rationalize manufacturing facilities company periodically recorded restructuring charges result company made estimates judgements regarding future plans including future termination benefits exit costs incurred restructuring actions take place actual results could vary estimates resulting adjustment earnings contingencies normal course business company subject contingencies legal proceedings claims arising business cover wide range matters including among others product liability environmental liability tax matters accordance sfas accounting contingencies company records accruals contingencies probable liability incurred amount loss reasonably estimated discussion contingencies reference made note income taxes note litigation matters restated consolidated financial statements income taxes december taxes provided approximately billion undistributed earnings foreign subsidiaries company invested invest undistributed earnings indefinitely future earnings repatriated united states company determines earnings remitted foreseeable future additional tax provisions would likely required due complexities tax laws assumptions would made practicable estimate amounts income taxes would provided company evaluates need deferred tax asset valuation allowance assessing whether likely realize deferred tax assets future assessment whether valuation allowance required often requires significant judgement including forecast future taxable income evaluation tax planning initiatives adjustments deferred tax valuation allowance made earnings period assessment made addition company operations tax jurisdictions located areas world subject audit jurisdictions tax audits nature often complex require several years resolve accruals tax contingencies require management make estimates judgements respect ultimate outcome tax audit actual results could vary estimates financial position cash cash equivalents time deposits marketable securities totaled billion december compared billion december approximately billion cash cash equivalents time deposits marketable securities held company 's foreign subsidiaries repatriation cash us may likely require additional tax provisions reflected restated consolidated financial statements discussion matter see critical accounting policiesincome taxes working capital restated billion december compared billion december resulting higher accrued liabilities due restructuring liabilities established increase deferred revenue consignment inventory cash cash equivalents time deposits marketable securities conversion workingcapital items expected fund nearterm operations company cash cash equivalents time deposits marketable securities december denominated primarily us dollar instruments nearterm maturities average interest yield cash cash equivalents december respectively interest yields time deposits marketable securities averaged respectively shortterm borrowings longterm debt december denominated primarily us dollars also include japanese yen longterm debt million result restatement company delayed filing quarterly report form q quarterly period ended september third quarter form q previously disclosed delay resulted breach company delivery sec filing obligations indenture indenture company jpmorgan chase bank formerly chase manhattan bank trustee company approximately billion longterm debt outstanding certain credit agreements gave certain rights trustee indenture respective lenders credit agreements accelerate maturity company 's indebtedness neither trustees respective lenders exercised right accelerate filing third quarter form q made concurrently filing cured noncompliance abovementioned obligations indenture credit agreements accordingly debt outstanding indenture credit agreements longer accelerated classified current company 's consolidated balance sheet company 's longterm credit ratings moody 's standard poor 's credit rating agencies reduced aaaaaa aa aa respectively december moody 's placed company 's longterm shortterm debt ratings review possible downgrade since company held discussions moody 's provided additional information requested facilitate review time company 's ratings remain credit review moody 's action taken internally generated cash provided operations restated basis billion billion billion cash provided operations continued company 's primary source funds finance operating needs expenditures new plants equipment part company 's ongoing commitment improve plant efficiency maintain superior research facilities company invested billion capital expansion past three years cash flow operations also included product liability payments pension contributionscash provided operations also used past three years pay dividends billion finance billion company 's share repurchase program fund business acquisitions including purchase patents trademarks cost million company 's share repurchase program authorizes company purchase common stock time time open market private transactions market conditions permit company purchased million shares common stock cost billion bringing total shares acquired since program 's inception million shares past three years company repurchased million shares cost billion employment levels december increased prioryear levels result dupont acquisition cautionary factors may affect future results annual report including documents incorporated reference written oral statements company makes time time contain certain forwardlooking statements within meaning section securities act section e securities exchange act identify forwardlooking statements fact use words expect anticipate estimate may project guidance intend plan believe words terms similar meaning expression connection discussion future operating financial performance one also identify forwardlooking statements fact relate strictly historical current facts forwardlooking statements based current expectations involve inherent risks uncertainties including factors could delay divert change could cause actual outcomes differ materially current expectations statements likely relate among things company 's goals plans projections regarding financial position results operations market position product development product approvals sales efforts expenses performance results current anticipated products outcome contingencies legal proceedings financial results based current expectations involve inherent risks uncertainties including factors could delay divert change next several years although possible predict identify factors may include following new government laws regulations health care reform initiatives united states state federal level countries ii changes fda foreign regulatory approval processes may cause delays approving preventing approval new products iii tax changes phasing tax benefits heretofore available united states certain foreign countries iv new laws regulations judicial decisions affecting pricing marketing competitive factors new products developed competitors lower prices superior performance features otherwise competitive bristolmyers squibb 's current products ii generic competition company 's products mature patents expire products iii technological advances patents attained competitors iv problems licensors suppliers distributors v business combinations among company 's competitors major customers difficulties delays inherent product development manufacturing sale products may appear promising development may fail reach market numerous reasons including efficacy safety concerns inability obtain necessary regulatory approvals difficulty excessive cost manufacture ii seizure recall products iii failure obtain imposition limitations use loss patent intellectual property rights iv failure comply current good manufacturing practices application regulations quality assurance guidelines could lead temporary manufacturing shutdowns product shortages delays product manufacturing v manufacturing distribution problems legal difficulties preclude delay commercialization products adversely affect profitability including intellectual property disputes ii adverse decisions litigation including product liability commercial cases iii inability obtain adequate insurance respect type liability iv recalls pharmaceutical products forced closings manufacturing plants v government investigations vi claims asserting violations securities antitrust laws vii environmental matters viii tax liabilities increasing pricing pressures worldwide including rules practices managed care groups institutional governmental purchasers judicial decisions governmental laws regulations related medicare medicaid healthcare reform pharmaceutical reimbursement pricing general fluctuations buying patterns inventory levels major distributors retail chains trade buyers may result seasonality pricing wholesaler buying decisions including effect incentives offered company 's wholesaler inventory management policies including workdown wholesaler inventory levels factors greater expected costs difficulties including unanticipated effects difficulties acquisitions dispositions events including obtaining regulatory approvals occurring connection evolving business strategies legal defense costs insurance expense settlement costs risk adverse decision related litigation changes advertising promotional spending categories spending may affect sales changes company 's structure resulting acquisitions divestitures mergers restructurings strategic initiatives economic factors company control changes business economic conditions including limited changes interest rates fluctuation foreign currency exchange rates changes business political economic conditions due recent terrorist attacks us threat future terrorist activity us parts world related us military action overseas changes accounting standards promulgated financial accounting standards board securities exchange commission american institute certified public accountants may require adjustments financial statements although company believes prudent plans assumptions assurance given goal plan set forth forwardlooking statements achieved readers cautioned place undue reliance statements speak date made company undertakes obligation release publicly revisions forwardlooking statements result new information future events otherwise item restated financial statements supplementary data restated consolidated financial statements supplementary data including notes restated consolidated financial statements set forth item revised reflect restatement company 's business segment reorganization became effective first quarter certain events occurring subsequent filing original bristolmyers squibb company consolidated statement earnings dollars millions except per share data restated restated restated earnings net sales cost products sold marketing selling administrative advertising product promotion research development acquired inprocess research development provision restructuring items gain sales businessesproduct lines incomeexpense net earnings continuing operations minority interest income taxes provision income taxes minority interest net taxes earnings continuing operations discontinued operations net earnings net gain disposal net earnings earnings per common share basic earnings continuing operations discontinued operations net earnings net gain disposal net earnings diluted earnings continuing operations discontinued operations net earnings net gain disposal net earnings average common shares outstanding basic diluted dividends declared per common share includes minority interest expense income unconsolidated affiliates accompanying notes integral part financial statements bristolmyers squibb company consolidated statement comprehensive income retained earnings dollars millions restated restated restated comprehensive income net earnings comprehensive income foreign currency translation net tax benefit taxes twelve months ended december tax benefit deferred losses derivatives qualifying hedges net tax benefit total comprehensive loss comprehensive income retained earnings retained earnings january net earnings cash dividends declared zimmer common stock dividend retained earnings december accompanying notes integral part financial statements bristolmyers squibb company consolidated balance sheet dollars millions december restated restated assets current assets cash cash equivalents time deposits marketable securities receivables net allowances inventories including consignment inventory prepaid expenses total current assets property plant equipment net goodwill intangible assets net assets total assets liabilities current liabilities shortterm borrowings deferred revenue consigned inventory accounts payable dividends payable accrued expenses accrued rebates returns us foreign income taxes payable total current liabilities liabilities longterm debt total liabilities commitments contingencies stockholders ' equity preferred stock convertible series authorized million shares issued outstanding liquidation value per share common stock par value per share authorized billion shares issued issued capital excess par value stock accumulated comprehensive loss retained earnings less cost treasury stock common shares total stockholders ' equity total liabilities stockholders ' equity accompanying notes integral part financial statements bristolmyers squibb company consolidated statement cash flows dollars millions year ended december restated restated restated cash flows operating activities net earnings depreciation amortization acquired inprocess research development provision restructuring items gain sales businessesproduct lines including discontinued operations operating items receivables inventories deferred revenue consigned inventory accounts payable accrued expenses income taxes product liability insurance recoverable pension contribution assets liabilities net cash provided operating activities cash flows investing activities proceeds sales time deposits marketable securities purchases time deposits marketable securities additions property plant equipment proceeds sales businessesproduct lines proceeds sale clairol acquisition dupont investment imclone business acquisitions including purchase trademarkspatents net net cash used provided investing activities cash flows financing activities shortterm borrowings longterm debt borrowings longterm debt repayments issuances common stock stock plans purchases treasury stock dividends paid net cash provided used financing activities effect exchange rates cash increase cash cash equivalents cash cash equivalents beginning year cash cash equivalents end year accompanying notes integral part financial statements bristolmyers squibb company notes restated consolidated financial statements throughout notes restated consolidated financial statements referenced amounts reflect balances amounts restated basis intercompany balances transactions eliminated note accounting policies basis consolidationthe consolidated financial statements include accounts bristolmyers squibb company majority owned subsidiaries use estimatesthe preparation financial statements conformity us generally accepted accounting principles gaap requires use estimates assumptions affect reported amounts assets liabilities disclosure contingent assets contingent liabilities date financial statements reported amounts revenues expenses reporting period significant assumptions employed estimates used determining values intangible assets restructuring charges accruals sales rebate return accruals legal contingencies tax assets tax liabilities well estimates used applying revenue recognition policy accounting retirement postretirement benefits including actuarial assumptions actual results could differ estimated results revenue recognitionthe company recognizes revenue sales upon shipment product customers except case certain transactions us pharmaceuticals wholesalers accounted using consignment model gaap revenue recognized substantially risks rewards ownership transferred case sales made wholesalers result incentives excess wholesaler 's ordinary course business inventory level time understanding agreement course dealing consistent business practice company would extend incentives based levels excess inventory connection future purchases time incentives would cover substantially vary directly wholesaler 's cost carrying inventory excess wholesaler 's ordinary course business inventory level substantially risks rewards ownership transfer upon shipment accordingly sales accounted using consignment model determination sales wholesaler meet foregoing criteria involves evaluation variety factors number complex judgments consignment model company recognize revenue upon shipment product rather upon shipment product company invoices wholesaler records deferred revenue gross invoice sales price classifies inventory held wholesalers consignment inventory company 's cost inventory company recognizes revenue consignment inventory longer subject incentive arrangements later inventory sold wholesalers ' customers firstin firstout fifo basis revenues reduced time sale reflect expected returns estimated based historical experience additionally provision made time sale discounts rebates estimated sales allowances based historical experience updated changes facts circumstances appropriate provision recorded reduction revenue sales rebate return accrualsmedicaid managed healthcare sales rebate sales returns accruals established period related revenue recognized resulting reduction sales establishment liability included accrued liabilities accrual recorded based estimate proportion recorded revenue result rebate prime vendor chargebacks established similar manner recorded reduction accounts receivable cash cash equivalentscash cash equivalents primarily include securities maturities three months less time purchase recorded cost approximates market value time deposits marketable securitiestime deposits marketable securities available sale recorded fair value approximates cost inventory valuationinventories generally stated average cost excess market capital assets depreciationexpenditures additions renewals improvements capitalized cost depreciation generally computed straight line method based estimated useful lives related assets estimated useful lives major classes depreciable assets years buildings years machinery equipment fixtures company periodically evaluates whether current events circumstances indicate carrying valueof depreciable assets may recoverable estimate undiscounted future cash flows produced asset appropriate group assets compared carrying value determine whether impairment exists capitalized softwarecertain costs obtain internal use software significant systems projects capitalized amortized estimated useful life software ranges four ten years costs obtain software projects significant expensed incurred investmentsthe company consolidates majority owned subsidiaries company accounts less owned companies ability exercise significant influence using equity method accounting company 's share net income losses equity investments included minority interest expense consolidated statement earnings company periodically reviews equity investments impairment adjusts investments fair value decline market value deemed temporary longterm investments securities comprises marketable equity securities securities investments market values readily available included assets marketable equity securities classified availableforsale reported fair value fair value based quoted market prices end reporting period unrealized gains losses reported net related tax effects component accumulated comprehensive income loss stockholders ' equity sold time sale gains losses calculated specific identification method recognized incomeexpense losses also recognized income decline market value deemed temporary securities investments market values readily available carried cost acquisitionsthe company adopted sfas business combinations statement requires companies use purchase method accounting business combinations initiated june goodwillin june financial accounting standards board fasb issued sfas goodwill intangible assets effective fiscal years beginning december sfas addresses initial recognition measurement intangible assets acquired outside business combination recognition measurement goodwill intangible assets subsequent acquisition new rules goodwill longer amortized subject annual impairment tests connection accounting change goodwill resulting company 's dupont pharmaceuticals acquisition imclone investment amortized goodwill arising business acquisitions prior july amortized straightline basis periods ranging years goodwill amortized december beginning january goodwill amortization expense longer recorded goodwill amortization expense million intangible assetsintangible assets consisting patents technology licenses amortized straightline basis periods ranging years representing remaining life assets accumulated amortization intangible assets million december million december amortization expense intangible assets million million million respectively intangible assets periodically reviewed impairment based assessment future operations including cash flows asset identified impaired written fair market value acquired inprocess research developmentthe fair value inprocess research development acquired business combination determined independent appraisal based present value research project 's projected cash flows utilizing income approach consistent aicpa practice aid assets acquired business combinations used research development activities focus software electronic devices pharmaceutical industries future cash flows predominately based net income forecast project consistent historical pricing margins expense levels similar products revenues estimated based relevant market size growth factors expected industry trends individual project life cycles life research project 's underlying patent determining fair value research project expected revenues first adjusted technical risk completion resulting cash flows discounted rate approximating company 's weighted average cost capital acquired process research development expensed incurred underlying product received regulatory approval future alternative use addition costs nonrefundable related acquisition licensing products yet received regulatory approval marketed alternative future use charged earnings incurred income taxesthe provision income taxes determined using asset liability approach accounting income taxes approach deferred taxes represent future tax consequences expected occur reported amounts assets liabilities recovered paid provision income taxes represents income taxes paid payable current year plus change deferred taxes year deferred taxes result differences financial tax bases company 's assets liabilities adjusted changes tax rates tax laws changes enacted valuation allowances recorded reduce deferred tax assets likely tax benefit realized company record provision income taxes undistributed earnings foreign subsidiaries expect repatriate foreseeable future product liabilityaccruals product liability recorded undiscounted basis probable liability incurred amount liability reasonably estimated based existing information accruals adjusted periodically assessment efforts progress additional information becomes available receivables related insurance thirdparty recoveries product liabilities recorded undiscounted basis probable recovery realized insurance recoverable recorded balance sheet general payment terms two years less amounts recognized excess related liabilities december million million respectively derivative financial instrumentsderivative financial instruments used company principally management interest rate foreign currency exposures company hold issue derivative financial instruments trading purposes company records derivative instruments balance sheet fair value changes derivative 's fair value recognized earnings unless specific hedge criteria met derivative designated fair value hedge changes fair value derivative hedged item attributable hedged risk recognized charge credit earnings derivative designated cash flow hedge effective portions changes fair value derivative recorded comprehensive income loss recognized consolidated statement earnings hedged item affects earnings cash flows classified consistent underlying hedged item purchased foreign currency options entire change fair value included measurement hedge effectiveness cash flow hedges ineffective portions changes fair value cash flow hedges recognized charge credit earningsthe company designates assigns derivatives hedges forecasted transactions specific assets specific liabilities hedged assets liabilities sold extinguished forecasted transactions hedged longer expected occur company recognizes gain loss designated hedging financial instruments shipping handling coststhe company typically charge customers shipping handling costs shipping handling costs included marketing selling administrative expenses million million million respectively advertising costsadvertising costs expensed incurred advertising expense million million million respectively stockbased compensationthe company applies accounting principles board apb opinion accounting stock issued employees related interpretations accounting stockbased compensation plans company recognize compensation expense stock options granted plans exercise price option date grant equal fair market value date grants restricted stock company recognizes compensation expense straightline basis period restrictions expire earnings per sharebasic earnings per common share computed using weightedaverage number shares outstanding year diluted earnings per common share computed using weightedaverage number shares outstanding year plus incremental shares outstanding assuming exercise dilutive stock options note restatement previously issued financial statements company experienced substantial buildup wholesaler inventories us pharmaceuticals business several years primarily buildup primarily due sales incentives offered company wholesalers incentives generally offered towards end quarter order incentivize wholesalers purchase products amount sufficient meet company 's quarterly sales projections established company 's senior management april company disclosed substantial buildup developed subsequently undertook plan work orderly fashion wholesaler inventory levels late october based review consideration previously disclosed buildup wholesaler inventories company 's us pharmaceuticals business incentives offered certain wholesalers advice company 's independent auditors pricewaterhousecoopers llp company determined required restate sales earnings correct errors timing revenue recognition certain sales certain us pharmaceuticals wholesalers since time company undertaken analysis transactions incentive practices us pharmaceuticals wholesalers company determined certain incentivized transactions certain wholesalers accounted consignment model rather recognizing revenue transactions upon shipment determination involved evaluation variety criteria number complex accounting judgments result analysis company determined certain sales two largest wholesalers us pharmaceuticals business accounted consignment model based part relationship amount incentives offered wholesalers amount inventory held wholesalers following determination restate sales earnings matters described company also determined would correct certain historical accounting policies conform accounting gaap certain known errors made application gaap previously recorded case company believed amount error material company 's consolidated financial statements addition part restatement process company investigated accounting practices certain areas involve significant judgments determined restate additional items respect company concluded errors made application gaap including certain revisions inappropriate accounting senior management set aggressive targets company 's businesses errors inappropriate accounting corrected restatement arose least part period unrealistic expectations consequent overestimation anticipated performance certain company 's products programs result foregoing company restated financial statements three years ended december including corresponding interim periods quarterly periods ended march june restatement affects periods prior impact restatement prior periods reflected adjustment opening retained earnings january connection audits restatement previously issued financial statements company 's consolidated financial statements year ended december company 's independent auditors pricewaterhousecoopers llp identified communicated company audit committee two material weaknesses defined standards established american institute certified public accountants relating company 's accounting public financial reporting significant matters initial recording management review oversight certain accounting matters last year company searched hired new chief financial officer outside company restaffed controller position created position chief compliance officer changed leadership pharmaceuticals group response wholesaler inventory buildup matters identified restatement adjustments direction audit committee last year senior management directed company dedicate resources take steps strengthen control processes procedures order identify rectify past accounting errors prevent recurrence circumstances resulted need restate prior period financial statements company also revised budgeting process emphasize bottomup approach contrast topdown approach company implemented review certification process annual quarterly reports securities exchange act amended well processes designed enhance monitoring wholesaler inventories addition company process expanding business risks disclosure group includes senior management including chief executive officer chief financial officer taking number additional steps designed create open environment communications flow information throughout company company continues identify implement actions improve effectiveness disclosure controls procedures internal controls including plans enhance resources training respect financial reporting disclosure responsibilities review actions audit committee independent auditors set forth restatement adjustments included restatement previously issued financial statements error within meaning accounting principles board opinion accounting changesrevenue recognition restatement adjustments consignment sales historically company recognized revenue sales upon shipment product customers gaap revenue recognized substantially risks rewards ownership transferred case sales made wholesalers result incentives excess wholesaler 's ordinary course business inventory level time understanding agreement course dealing consistent business practice company would extend incentives based levels excess inventory connection future purchases time incentives would cover substantially vary directly wholesaler 's cost carrying inventory excess wholesaler 's ordinary course business inventory level substantially risks rewards ownership transfer upon shipment accordingly sales accounted using consignment model analysis based staff accounting bulletin revenue recognition financial statements topic question sec observer 's comment eitf issue vendor income statement characterization consideration paid reseller vendor 's products codified eitf issue example payment reseller financing costs determination sales wholesaler meet foregoing criteria involves evaluation variety factors number complex judgments consignment model company recognize revenue upon shipment product rather upon shipment product company invoices wholesaler records deferred revenue gross invoice sales price classifies inventory held wholesalers consignment inventory company 's cost inventory company recognizes revenue net discounts rebates estimated sales allowances accruals returns consignment inventory longer subject incentive arrangements later inventory sold wholesalers ' customers firstin firstout fifo basis company restated previously issued financial statements correct timing revenue recognition certain previously recognized us pharmaceuticals sales cardinal mckesson two largest wholesalers company 's us pharmaceuticals business based application criteria described recorded error time shipment accounted using consignment model company determined shipments product cardinal shipments product mckesson met consignment model criteria set forth july july respectively case continuing end period thereafter accordingly consignment model required applied shipments prior respective periods company recognized revenue respect sales cardinal mckesson upon shipment product although company generally views approximately one month supply desirable level wholesaler inventory goingforward basis level wholesaler inventory representative industry average applying consignment model sales cardinal mckesson company defined inventory excess wholesaler 's ordinary course business inventory level inventory two weeks three weeks supply respectively based levels inventory cardinal mckesson required used basis negotiation incentives granted result restatement adjustment net sales reduced million million million respectively corresponding reduction earnings continuing operations minority interest income taxes million million million respectively separately discussion march company entered distribution agreement mckesson provision warehousing order fulfillment services company 's oncology therapeutics network otn specialty distributor anticancer medicines related products terms agreement mckesson purchases oncology products service otn 's fulfillment needs number vendors including company subsequent shipment product mckesson company significant continuing involvement transaction including marketing product enduser invoicing customer collecting receivables customer behalf mckesson addition otn keeps credit risk responsible shipping costs customer prior restatement company recorded error sales agreement upon shipment product mckesson company restated previously issued financial statements account sales using consignment model defer recognition revenue products sold mckesson resulting reduction net sales earnings continuing operations minority interest income taxes million million respectively year ended december sales returns historically company recorded returns based actual product returns period although accounting policy accordance gaap accordingly error company believed amount error material time level returns consistently low absolute dollar basis company 's practice historically approximated accrual method accounting material respects part restatement company adopted accrual method accounting returns conform gaap restatement adjustment reduced opening retained earnings january million give effect amounts affecting periods prior reduced net sales earnings continuing operations minority interest income taxes years ended december million million million respectively sales rebate accrual company restated medicaid prime vendor rebate liabilities us pharmaceuticals business correct error determination accrual important component determining required accrual estimate amount inventory wholesalers sold upon company expects pay rebate company experienced substantial buildup wholesaler inventories us pharmaceuticals business several years primarily accrual fully reflect growth inventory levels first quarter company determined estimated medicaid prime vendor sales rebate accrual balance us pharmaceuticals business understated recorded onetime adjustment accrual resulted decrease sales earnings approximately million million respectively part restatement company correctly considered inventory wholesalers reversed previously recorded first quarter onetime adjustment restatement also attributable part impact consignment sales adjustment deferral certain previously recognized sales resulted deferral recording related rebates company also recorded restatement adjustment correct error methodology establishing managed healthcare sales rebate accruals accrue estimate rebates time sale rather ratably period managed health care entities perform obligations agreements providing rebates medicaid prime vendor rebates discussed estimated amount inventory wholesalers sold upon company expects pay rebate important component determining required accrual previously impact excess inventory held wholesalers erroneously considered determination accrualthe restatement adjustments medicaid prime vendor managed care rebates reduced opening retained earnings january million give effect amounts affecting periods prior reduced net sales earnings continuing operations minority interest income taxes year ended december million increased net sales year ended december million increased net sales earnings continuing operations minority interest income taxes year ended december million million respectively restatement adjustments capitalized research development payments prior company 's investment imclone fourth quarter company 's accounting policy payments related acquisition license patent rights capitalize payments regardless whether underlying asset received marketing approval fda regulatory agencies company 's prior accounting policy based principle payments made acquire license products capitalized amortized period company expected would benefit revenue stream associated underlying product research development term depending arrangement capitalized payments subsequently amortized earnings using straightline method term agreement expected life underlying product policy accordance gaap accordingly error gaap requires incurred costs related acquisition licensing products yet received regulatory approval marketed alternative future use charged earnings part restatement company corrected accounting policy payments related acquisition license patent rights conform gaap result opening retained earnings reduced january million give effect amounts affecting periods prior earnings continuing operations minority interest income taxes years ended december increased million million respectively earnings continuing operations minority interest income taxes year ended december reduced million irbesartan transaction fourth quarter company sanofisynthelabo sanofi modified existing codevelopment arrangement irbesartan avapro form alliance company contributed irbesartan intellectual property company owns interest sanofi owns interest profits shared proportion ownership interest sanofi agreed pay company million million fourth quarters respectively company accounts transaction sale interest license defers amortizes million payment income expected useful life license company 's previous accounting based determination useful life license due anticipated fda approval competing product company reviewed accounting transaction determined previous amortization based anticipated approval competing product accordance gaap accordingly error approval competing product received part restatement company corrected error amortizing million payment remaining patent life approximately eleven years consequently earnings continuing operations minority interest income taxes year ended december reduced million acquisition liabilities company recorded certain liabilities contingencies identified date acquisition connection acquisitions period subsequent periods substantial portions liabilities determined excess reversed income except amounts related dupont acquisition reversed goodwill based investigation accounting practices certain areas involve significant judgments company determined certain portions liabilities established inappropriately appear related quantifiable specific category liability supporting establishment portions liabilities amounts ultimately inappropriately reversed restatement company adjusted goodwill liabilities dates acquisition reversed amounts inappropriately recognized income subsequent periods addition company recorded error million acquisition costs paidin capital connection acquisition redmond products inc leading us hair care manufacturer accounted using poolingofinterests accounting method company determined classification costs paidin capital error amount million charged expense resulting decrease opening retained earnings january based investigation accounting practices certain areas involve significant judgments company determined remaining million established inappropriately appear related quantifiable specific category liability supporting establishment amount million restated described following table presents amounts pretax acquisition reserves inappropriately established reversed income year reserves amounts inappropriately inappropriately established reversed dollars millions pre totals aggregate effect restatement transactions decreased opening retained earnings january approximately million give effect amounts affecting prior periods addition adjustment redmond acquisition described increased additional paidin capital component stockholders ' equity million adjustments also decreased goodwill million decreased earnings continuing operations minority interest income taxes million million years ended december respectively divestiture liabilitiesin connection divestiture transactions consummated period company recorded certain liabilities contingencies identified date divestiture subsequent periods substantial portions liabilities determined excess reversed income based investigation accounting practices certain areas involve significant judgments company determined certain portions liabilities established inappropriately appear quantifiable specific category liability supporting establishment portions liabilities amounts ultimately inappropriately reversed accordingly company eliminated amounts inappropriately recognized income subsequent periods increased gain sale periods related divestiture equal amount addition company determined certain liabilities inappropriately established reduction equity connection spinoff zimmer accordingly company reversed establishment liabilities following table presents amounts pretax divestiture reserves inappropriately established reversed income year reserves amounts inappropriately inappropriately established reversed dollars millions pre totals includes reserves inappropriately established inappropriately reversed million million respectively related discontinued operations represents amounts inappropriately reversed together amounts corrected restatement restatement adjustments increased opening retained earnings january million give effect amounts affecting periods prior decreased earnings continuing operations minority interest income taxes million million years ended december respectively increased earnings continuing operations minority interest income taxes million year ended december addition net gain sale discontinued operations increased million million years ended december respectively zimmer spinoff dividend decreased million corresponding decrease accrued liabilities restructuring items period company recorded restructuring asset writedown charges connection decision exit certain activities streamline operations based investigation accounting practices certain areas involve significant judgments company determined certain charges established error including inappropriately established classified provision restructuring items statement earnings part restatement respect company reversed million million recorded restructuring expenses liabilities established error million related liabilities inappropriately established asset writedowns restructuring expenses primarily manufacturing facility closures management yet committed million expenses related discontinued operations erroneously recorded restructuring expenses charges partially offset million items inappropriately charged restructuring liability million costs inappropriately established error restructuring expense respect certain operating expense items established restructuring expenses error previously corrected amount error material company 's consolidated financial statements addition certain operating items million inappropriately classified error restructuring expenses million related discontinued operations company also determined million restructuring charges related closure research facility classified error research development expense addition company reclassified certain writeoffs inventory made connection restructuring actions million million respectively restructuring expense cost products sold bristolmyers squibb company notes restated consolidated financial statements note restatement previously issued financial statements continued company recorded error writeoff certain receivables exited product lines approximately million restructuring non recurring charges company recorded restatement adjustment properly record writeoff receivables reduction net sales aggregate adjustment restructuring items resulted increase earnings continuing operations minority interest income taxes million million years ended december respectively litigation accrual adjustment sunday march company entered binding letter agreement watson pharmaceuticals inc settle lawsuit relating buspar gaap million charge incurred letter agreement accrued fourth quarter letter agreement entered prior original issuance consolidated financial statements filed april company erroneously accrued million charge first quarter part restatement company restated charge recognize fourth quarter accordingly earnings continuing operations minority interest income taxes year ended december reduced million related busparlitigation income taxes sfas impact recorded intercompany sales inventory related product ultimately sold unrelated third party intercompany sales consolidated subsidiaries located different tax jurisdictions current tax expense liability recognized country sale corresponding offsetting deferred tax benefit asset recognized offset tax product sold unrelated third party part restatement company recorded adjustment correct erroneous calculation deferred tax asset related intercompany profit inventory intercompany royalties reflect impact intercompany profit inventory intercompany royalties consignment sales restatement adjustment discussed restatement adjustment reduced opening retained earnings january million decreased net earnings million increased net earnings million million respectively cumulative adjustment net deferred tax assets increase million december net decreases million million december respectively fourth quarter company erroneously reduced deferred tax benefit related acquired inprocess research development due inappropriate conclusion regarding realization related deferred tax assets company erroneously determined deferred tax asset associated purchase price premium paid tender offer imclone stock recorded due uncertainty realization company restated deferred tax asset fourth quarter recognizing deferred tax benefit million additionally company recognized excess liabilities related income tax contingencies due error determining interest relating recorded tax liabilities error resulted use incorrect interest rate part restatement company restated income taxes payable december recognizing current benefit million reflect tax impact pretax restatement adjustments described herein income tax expense adjusted restated annual period tax impact restatement adjustments increase opening retained earnings million january reduce tax provision increase earnings continuing operations including taxes minority interest million million million years ended december respectively tax provision increased net earnings discontinued operations reduced million million result restatement adjustments cumulative adjustment related pretax adjustment items continuing operations including minority interest increase net deferred tax assets million million million december respectively dividend accrual historically company recognized liability declared dividends record date typically approximately two weeks declaration date accounting policy accordance gaap accordingly error declaration lawful dividend creates laws state company 's incorporation obligation part corporation declaration date requires recognition dividend accrual date part restatement company corrected accounting policy record liability dividends declaration date restatement resulted reduction million opening retained earnings january give effect amounts affecting periods prior corresponding increase dividends payable stockholders ' equity dividends payable similarly restated million million million years ended december respectively revision restatement items first quarter company entered likekind exchange agreement respect certain aircraft erroneously recognized pretax gain million time recognizing excess proceeds received upon tradein recorded net book value gain rather reduction basis new aircraft part restatement company corrected error resulted decrease million opening retained earnings january give effect amounts affecting prior periods reflect reduction book value aircraft acquired million addition company determined portion accrued liability employee medical benefits inappropriately reversed certain insurance retirement costs inappropriately charged discontinued operations corrected errors restatement adjustment increased earnings continuing operations minority interest income taxes years ended december million million respectively summary restatement items following table presents effects restatement adjustments net sales increase decrease net sales year ended december dollars millions net sales previously reported adjustments consignment sales sales returns sales rebate accruals restructuring items decrease net sales net sales restated result restatement application consignment model approximately million sales calculated net customary early pay cash discounts recognized error period reversed amount approximately million expected recognized approximately million projected recognized following table presents effects restatement adjustments earnings continuing operations minority interest income taxes earnings continuing operations net earnings gain sale discontinued operations year ended december dollars millions earnings continuing operations minority interest income taxes previously reported revenue recognition restatement adjustments consignment sales sales returns sales rebate accruals subtotal restatement adjustments capitalized research development payments irbesartan transaction acquisition liabilities divestiture liabilities restructuring items litigation accrual adjustment restatement items subtotal total restatement adjustments earnings continuing operations minority interest income taxes restated provision income taxes previously reported tax related restatement adjustments tax restatement adjustments minority interest net taxes earnings continuing operations restated net earnings gain disposal discontinued operations previously reported adjustment divestiture liabilities net earnings gain disposal sale discontinued operations restated minority interest included expense pretax basis originally reported minority interest shown together income unconsolidated affiliates net taxes earnings continuing operations income taxes consolidated statement earnings therefore amounts previously reported reclassified comparable basis following table presents impact restatement adjustments affecting periods prior stockholders ' equity january increase decrease stockholders ' equity dollars millions stockholders ' equityjanuary previously reported sales returns sales rebate accruals capitalized research development payments acquisition liabilities divestiture liabilities restatement items deferred taxes intercompany profit dividend accrual decrease stockholders ' equity stockholders ' equityjanuary restated following tables present impact restatement adjustments company 's previously reported results condensed basis year ended december previously previously previously reported restated reported restated reported restated dollars millions except per share data statement operations net sales total costs expenses earnings continuing operations discontinued operations net earnings net gain disposal net earnings basic earnings per common share continuing operations discontinued operations net earnings net gain disposal net earnings diluted earnings per common share continuing operations discontinued operations net earnings net gain disposal net earnings balance sheet cash marketable securities receivables net inventories including consignment inventory prepaid expenses total current assets property plant equipment net goodwill intangible assets net assets total assets shortterm debt borrowings deferred revenue consigned inventory current liabilities total current liabilities longterm debt longterm liabilities total liabilities stockholders ' equity total liabilities stockholders ' equity bristolmyers squibb company notes restated consolidated financial statements note discontinued operations company announced planned divestitures clairol zimmer businesses accordingly operations clairol includes matrix essentials inc matrix affiliate zimmer reflected discontinued operations consolidated statement earnings november company completed sale clairol procter gamble cash proceeds approximately billion sale resulted pretax gain billion billion taxes restated included gain disposal discontinued operations august company spun zimmer holdings inc taxfree distribution resulting common stock dividend million restated company completed sale matrix cosmair inc wholly owned us subsidiary l'oreal sa resulting pretax gain million million taxes restated gain included gain disposal discontinued operations net sales earnings discontinued operations follows dollars millions net sales earnings income taxes income taxes net earnings discontinued operations earnings income taxes year ended december include restructuring charges million consolidated balance sheet consolidated statement cash flows include clairol zimmer businesses date disposition net assets discontinued operations december million consisting current assets million longterm assets million less liabilities principally current million company uses centralized approach cash management financing operations accordingly company allocate debt businesses cash flows operating investing activities discontinued operations years ended december billion including approximately billion proceeds sale clairol million including million proceeds sale matrix million respectively note acquisitions divestitures dupont pharmaceuticals acquisition october company acquired dupont pharmaceuticals business dupont e du pont de nemours company billion cash results dupont included consolidated financial statements date acquisition dupont primarily domestic pharmaceutical imaging product business focused research development acquisition financed proceeds issuance billion commercial paperthe issuance billion mediumterm notes internal cash flows purchase price allocation prepared preliminary basis certain changes expected additional information becomes available following summary estimated fair values assets acquired liabilities assumed date acquisition restated dollars millions current assets property plant equipment intangible assets acquired inprocess research development goodwill assets total assets acquired current liabilities restructuring liabilities acquisition liabilities long term liabilities total liabilities assumed purchase price total intangible assets million amortized weightedaverage useful lives include core developed technology million years weightedaverage useful life respectively patents million year weightedaverage useful life goodwill million assigned pharmaceuticals reporting unit total amount million expected deductible tax purposes year period value million assigned acquired inprocess research development charged earnings fourth quarter charge associated five research projects cardiovascular central nervous system oncology antiinfective therapeutic areas ranging preclinical phase ii development stage amount determined identifying research projects technological feasibility established alternative future use projected fda approval dates years time company expected projects begin generate cash flows cost complete research projects estimated billion research development projects considered valuation subject normal risks uncertainties associated demonstrating safety efficacy required obtain fda approval company terminated one projects antiinfective therapeutic area connection acquisition company recorded million restructuring liabilities result severance relocation workforce elimination duplicate facilities contract terminations costs recognized company liability assumed acquisition date resulting additional goodwill restructuring liabilities consisted million employee termination benefits approximately employees million related closure facilities million contract terminations million originally recorded accrued expenses reduced million december following unaudited pro forma financial information presents results acquisition occurred beginning respective periods restated restated dollars millions except per share data net sales net earnings earnings per sharebasic earnings per sharediluted pro forma results prepared comparative purposes include certain adjustments additional amortization expense result identifiable intangible assets arising acquisition increased interest expense acquisition debt pro forma net earnings earnings per share amounts include billion gain sale clairol pro forma results necessarily indicative either results operations actually would resulted acquisition effect beginning respective periods future results company completed sale corzide delestrogen florinef three pharmaceutical products licensing rights corgard us estrace tablets apothecon commodity business viactiv solage product lines resulted pretax gain million company completed sale three pharmaceutical productsestrace cream ovcon ovcon well sea breeze brand japan resulting pretax gain million june company acquired calctose nutritional milk modifier million september company entered development andcommercialization agreement aripiprazole novel drug study phase iii trials treatment schizophrenia otsuka pharmaceutical co ltd connection agreement company made payments million million expensed inprocess research development december company completed sale laboratori guieu spa gynecologic pediatric dermatologic products business headquartered milan italy pretax gain million bristolmyers squibb company notes restated consolidated financial statements note restructuring items activities company recorded pretax restructuring charges restated basis million restructuring programs included termination benefits asset writedowns costs implemented downsize streamline operations rationalize manufacturing facilities terminate certain sales force research contract obligations time recorded actions expected substantially completed within twelve months expected substantially complete early additional costs associated restructuring projects year include million deductions customer charge backs relating abandoned nonstrategic pharmaceutical product lines included reduction sales restated million related inventory writeoffs included cost products sold restated current year restructuring charges offset reversal million result change estimate relating separation costs cancellation projects previously provided charge restated consisted million employee termination benefits approximately employees severance actions result company wide restructuring effort downsize streamline operations impact virtually areas including sales force manufacturing administration research personnel addition million accrued termination contract sales force million accrued exit costs primarily related costs associated closure certain manufacturing operations charge also included million fixed asset writedowns million asset writedowns primarily related exit nutritionals business eastern europe closure pharmaceutical production facility us closure research facility france following table presents detail charges restated operating segment type company allocate restructuring charges business segments restated restated employee asset restated restated employee termination write exit restated terminations benefits downs costs items totals dollars millions except employee terminations data pharmaceuticals nutritionals healthcare corporateother totals reduction reserves changes estimates restructuring items reflected statement earnings items recorded restated include pretax charge million settlement litigation promotion claims brought distributor store brand infant formula meadjohnson buspar patent litigation million contribution bms foundation million establish additional reserves future breast implant claims million costs associated product recall activities company recorded pretax restructuring charges restated million restructuring programs included termination benefits asset writedowns costs implemented consolidate us sales force rationalize manufacturing facilities downsize streamline operations additional costs associated restructuring projects year include million related inventory writeoffs included cost products sold restated actions substantially complete charge restated consisted million employee termination benefits approximately employees severance actions focused sales force manufacturing administrative personnel addition million costs recorded consisting mainly certain contract termination facility remediation expenses charge also included million asset writedowns primarily related exit research facility japan manufacturing operations us certain international operations convatec addition assets million written consisted primarily capitalized software longer used result sales force actions described following table presents detail charges restated operating segment type company allocate restructuring charges itsbusiness segments restated restated restated employee asset employee termination write exit restated restated terminations benefits downs costs items totals dollars millions except employee terminations data pharmaceuticals nutritionals healthcare corporateother totals items recorded restated include million contribution bms foundation million costs associated product recall following table presents restructuring charges spending liabilities associated prior current actions restated restated employee termination exit cost restated liability liability total dollars millions balance december charges spending changes estimates balance december charges spending changes estimates balance december note earnings per share computations basic earnings per common share diluted earnings per common share follows restated restated restated dollars shares millions except per share data net earnings continuing operations discontinued operations net earnings net gain disposal net earnings basic average common shares outstanding earnings continuing operations discontinued operations net earnings net gain disposal net earnings diluted average common shares outstanding incremental shares outstanding assuming exercise dilutive stock options weighted average sharesdiluted earnings continuing operations discontinued operations net earnings net gain disposal net earnings weightedaverage shares issuable upon exercise stock options included diluted earnings per share calculation dilutive million million million note income expense year ended december restated restated restated dollars millions interest income interest expense foreign exchange gains losses net income expense net interest paid million million million respectively net primarily amortization goodwill capitalized software partially offset insurance settlements royalty income net also includes payments relating product collaboration agreement ivax corporation note alliances investments november company purchased million shares imclone systems incorporated imclone per share million represented approximately imclone shares outstanding prior commencement public tender offer transaction accounted using equity method accounting imclone biopharmaceutical company focused developing targeted cancer treatments include growth factor blockers cancer vaccines antiangiogenesis therapeutics equity investment imclone part strategic agreement company imclone also includes arrangement codevelop copromote investigational cancer drug erbitux series payments totaling billion company paid imclone milestone payment million march agreement imclone revised reduce total payments million billion revised agreement company paid imclone million first quarter million march pay aggregate million upon achievement two milestones also revised agreement company pay imclone distribution fee based flat rate product revenues north america fourth quarter transactions resulted pretax charge approximately million comprised million writeoff acquired process research development related equity investment million writeoff portion million milestone payment remaining million million milestone payment recorded additional equity investment eliminate income statement effect portion milestone payment company economic claim ownership interest imclone million milestone payment made revised agreement million expensed inprocess research development first quarter remaining million recorded additional equity investment eliminate income statement effect portion milestone payment company economic claim ownership interest imclone acquired inprocess research development charge related three oncology research projects phase later stage development one research project erbitux late phase iii development amount determined identifying research projects areas technological feasibility established alternative future use projected us food drug administration fda approval dates used years time company expects projects begin generate cash flows cost complete projects estimated million research development projects considered valuation subject normal risks uncertainties associated demonstrating safety efficacy required obtain fda approval purchase price allocation resulted million patent technology intangible assets amortized overtheir weightedaverage useful lives years approximately million goodwill amortized december imclone announced fda refused accept filing biologics license application bla submitted imclone erbitux bla submitted gain marketing approval treat irinotecanrefractory colorectal carcinoma january subcommittee oversight investigations house energy commerce committee announced investigating questions conduct imclone development erbitux january imclone announced received informal inquiry securities exchange commission well inquiries department justice aforementioned subcommittee company cooperating investigations million paid equity investment million milestone payment million million expensed acquired inprocess research development remaining million recorded equity investment additional million recorded investment primarily acquisition costs resulting carrying value million december pershare basis carrying value company 's imclone investment closing market value imclone shares december respectively third quarter company recorded pretax charge earnings million temporary decline market value imclone fair value equity investment imclone used determine charge based market value imclone shares september december imclone total assets million total stockholders ' deficit million accumulated deficit million year ended december imclone million net loss company process assessing impact fasb interpretation consolidation variable interest entities consolidated financial statements based preliminary analysis impact fin company believes reasonably possible imclone meet criteria considered variable interest entity relation company company sanofisynthelabo sanofi entered codevelopment comarketing agreement two products avapro irbesartan angiotensin ii receptor antagonist indicated treatment hypertension plavix clopidogrel platelet inhibitor worldwide alliance operates framework two geographic territories one americas australia europe asia two territory partnerships formed manage central expenses marketing research development royalties supply finished product individual countries country level agreements either copromote whereby partnership formed parties sell brand comarket whereby parties operate sell brands independently place company acts operating partner territory covering americas principally us canada puerto rico latin american countries australia owns majority controlling interest territory company consolidates country partnership results territory records sanofi 's share results minority interest expense company recorded sales territory comarketing countries million million million respectively case restated sanofi acts operating partner territory covering europe asia owns majority controlling interest territory company accounts investment partnership entities territory equity method records share results net income unconsolidated affiliates included together minority interest net taxes income taxes partnership entities years ended december million million million respectively note income taxes components earnings loss continuing operations minority interest income taxes year ended december restated restated restated dollars millions us nonus amounts categorized based location taxing authorities provision income taxes attributable continuing operations consisted year ended december restated restated restated dollars millions current us nonus deferredus nonus company 's provision income taxes different amount computed applying statutory us federal income tax rate earnings continuing operations minority interest income taxes result following earnings minority interest income taxes restated restated restated dollars millions earnings continuing operations minority interest income taxes us statutory rate effect operations ireland puerto rico switzerland state local taxes foreignother effective tax rate continuing operations declined due primarily lower pretax income us resulting write acquired inprocess research development nonrecurring items restated basis effective rate also reduced amount originally reported result impact tax matters discussed note restatement previously issued financial statements consolidated financial statements increase effective tax rate benefit operations ireland puerto rico switzerland reflects greater percentage total pretax income generated jurisdictions tax rates lower us statutory tax rate prepaid taxes december million million respectively deferred income taxes included assets liabilities december million million respectively components prepaid deferred income taxes consisted year ended december restated restated dollars millions acquired inprocess research development consignment inventory items restructuring acquisition divestiture reserves sales returns allowances depreciation net increase net prepaid deferred tax assets million december million december relates primarily acquired process research development consignment inventory items well restructuring acquisition divestiture reserve charges give rise tax deductions future years bristolmyers squibb company notes restated consolidated financial statements note income taxes continued income taxes paid year million million million respectively us federal income taxes provided substantially unremitted earnings nonus subsidiaries since management 's practice intent reinvest earnings operations subsidiaries total amount net unremitted earnings nonus subsidiaries approximately billion december certain tax contingencies exist probable reasonably estimable amounts included taxes payable december certain tax contingencies either considered probable reasonably estimable company time although company reasonably estimate possible amount contingency possible contingencies could material effect changes estimates related unresolved tax matters included foreignother rate reconciliation company settled us federal income tax returns internal revenue service subsequent end three months ended september company recognized income tax benefit million due settlement certain tax matters determination company expected settlement ongoing tax litigation existed december current tax benefit realized upon exercise stock options charged capital excess par amounted million million million respectively note accounts receivable december restated restated dollars millions accounts receivabletrade accounts receivablemiscellaneous less allowances receivables receivables net allowances receivables includes allowances bad debts note inventories december restated restated dollars millions finished goods work process raw packaging materials consignment inventory total inventory inventories discontinued operations constituted approximately total company inventory december note property plant equipment december restated restated dollars millions land buildings machinery equipment fixtures construction progress less accumulated depreciation property plant equipment discontinued operations constituted approximately total company property plant equipment december note shortterm borrowings longterm debt included shortterm borrowings amounts due banks primarily foreign million million december respectively andcurrent installments longterm debt million december million december weighted average interest rate shortterm borrowings current installments longterm debt december respectively company consolidated two credit facilities aggregating million syndicate lenders support commercial paper program new credit facility consists million fiveyear revolving credit facility extendable anniversary date consent lenders borrowings outstanding credit facility december addition company unused shortterm lines credit foreign banks million components longterm debt december dollars millions notes due notes due debentures due debentures due debentures due various rate yen term loans due yen notes due yen notes due deutsche mark interest yen principal term loan due industrial revenue bonds due yen term loan due variable rate industrial revenue bonds due capitalized leases due varying amounts longterm debt december increased million million december largely result financing dupont imclone transactions company issued billion debt notes billion matures remaining billion matures effective interest rates two notes respectively effective interest rates issuances approximated stated interest rate payments due period total dollars millions longterm debt company option redeem time portion notes redemption price equal sum principal amount notes redeemed plus accrued interest redemption date premium face value paid redeem notes result restatement company delayed filing quarterly report form q quarterly period ended september third quarter form q previously disclosed delay resulted breach company delivery sec filing obligations indenture indenture company jpmorgan chase bank formerly chase manhattan bank company approximately billion longterm debt outstanding certain credit agreements gave certain rights trustee indenture respective lenders credit agreements accelerate maturity company 's indebtedness neither trustee respective lenders exercised right accelerate filing third quarter form q made concurrently filing cured noncompliance abovementioned obligations indenture credit agreements accordingly debt outstanding indenture credit agreements longer accelerated therefore classified current company 's consolidated balance sheet note stockholders ' equity changes capital shares capital excess par value stock shares common stock restated capital excess par value issued treasury stock balance december issued pursuant stock plans options conversions preferred stock purchases balance december issued pursuant stock plans options conversions preferred stock purchases balance december issued pursuant stock plans options conversions preferred stock purchases balance december share company 's preferred stock convertible shares common stock callable company 's option reductions number issued shares preferred stock due conversions shares common stock dividends declared per common share accumulated balances related component comprehensive income loss follows deferred loss accumulated comprehensive foreign currency translation effective hedges loss dollars millions balance december adoption sfas comprehensive income loss balance december stock compensation plans company 's stock incentive plan officers directors key employees may granted options purchase company 's common stock less market price date option granted options generally become exercisable installments per year first fourth anniversaries grant date maximum term years additionally plan provides granting stock appreciation rights whereby grantee may surrender exercisable options receive common stock andor cash measured excess market price common stock option exercise price plan also provides granting performancebased stock options certain key executives terms stock incentive plan amended additional shares authorized amount outstanding shares per year plan incorporates company 's longterm performance awards addition stock incentive plan provides granting shares common stock key employees subject restrictions continuous employment except case death normal retirement restrictions generally expire fiveyear period date grant compensation expense recognized restricted period straightline basis december total restricted shares outstanding plan teamshare stock option plan fulltime employees excluding key executives meeting certain years service requirements granted options purchase company 's common stock market price date options granted company authorized shares issuance plan individual grants generally became exercisable third anniversary grant date december shares exercised plan company applies accounting principles board opinion accounting stock issued employees related interpretations accounting plans accordingly compensation expense recognized stockbased compensation plans restricted stock performancebased awards compensation cost company 's stock option plans determined based upon fair value grant date awards plans consistent methodology prescribed sfas accounting stockbased compensation company 's net income earnings per share would reduced unaudited pro forma basis approximately million per common share basic diluted million per common share basic diluted million per common share basic diluted fair value options granted estimated per common share per common share per common share respectively date grant using blackscholes optionpricing model following assumptions dividend yield volatility riskfree interest rate assumed forfeiture rate expected life years stock option transactions wereweighted average shares shares exercise price shares available option plan plan plan balance december authorized granted exercised lapsed balance december authorized granted exercised lapsed balance december authorized granted granted result zimmer spinoff exercised lapsed balance december effective spinoff zimmer august unexercised bristolmyers squibb stock options held zimmer employees converted zimmer stock options remaining unexercised bristolmyers squibb stock options number stock options exercise price adjusted preserve intrinsic value stock options ratio exercise price fair value existed prior spinoff following table summarizes information concerning currently outstanding exercisable options options outstanding options exercisable weighted average weighted average weighted average range exercise remaining contractual exercise number exercise prices number outstanding life price exercisable price december shares common stock reserved issuance pursuant stock plans options conversions preferred stock options related discontinued operations included amounts material bristolmyers squibb company notes restated consolidated financial statements note financial instruments company exposed market risk due changes currency exchange rates interest rates result company utilizes foreign exchange option forward contracts offset effect exchange rate fluctuations anticipated foreign currency transactions primarily intercompany inventory purchases expected occur within next year company exposures net foreign currency denominated assets liabilities approximated million million december respectively primarily europe japan mexico canada company mitigates effect exposures thirdparty borrowings exposures net foreign currency denominated assets liabilities related discontinued operations included amounts material foreign exchange option contracts forward contracts used hedge anticipated transactions company 's primary foreign currency exposures relation us dollar japanese yen euro mexican peso canadian dollar notional amounts company 's foreign exchange derivative contracts december million million respectively derivatives qualify hedges future cash flows effective portion changes fair value temporarily recorded comprehensive income recognized earnings hedged item affects earnings ineffective portion hedges reported earnings occurs notional amounts foreign exchange derivative contracts related discontinued operations included amounts material manage interest rate risk company utilizes interest rate swap contracts company enters interest rate swaps hedge effects adverse changes interest rates future cash outflows interest gains losses changes fair value interest rate swap contracts designated cash flow hedges initially deferred recorded comprehensive income amounts transferred comprehensive income recognized earnings interest expense period hedged item recognized earningsin company entered interest rate hedge contracts notional amount billion manage exposure changes interest rates longterm fixedrate debt issues connection dupont imclone transactions see note acquisitions divestitures note alliances investments restated consolidated financial statements contracts designated hedges variability cash flows due changes longterm benchmark interest rates third quarter company settled existing interest rate hedge contracts coincided issuance long term fixedrate debt company recorded contract settlements fair value resulting million deferred loss net taxes accumulated comprehensive incomeloss recognized yield adjustment terms related borrowings fair value derivative instruments recorded prepaid expenses december million fair values company 's derivative instruments based relevant market information including current forward currency exchange rates current interest rates fair value option contracts estimated using blackscholes model based yearend currency rates fair value foreign exchange forward contracts based yearend forward currency rates carrying amount company 's financial instruments include cash equivalents marketable securities accounts receivable longterm debt accounts payable approximates fair value december accordance sfas company recorded transition adjustment january million net taxes comprehensive incomeloss record derivative instruments fair value reconciliation current period changes net taxes included comprehensive incomeloss follows millions transition adjustment january net current period decreases fair value net recognized earnings net balance december portion ending balance included comprehensive income loss expected reclassified earnings next twelve months approximately million loss note segment information effective first quarter company reorganized three groups support pharmaceutical company related healthcare businesses result reorganization company three reportable segmentspharmaceuticals nutritionals healthcare pharmaceuticals segment comprised global pharmaceutical international excluding japan consumer medicines businesses nutritionals segment consists mead johnson nutritionals primarily infant formula business healthcare segment consists convatec medical imaging consumer medicines us japan businesses company 's products sold principally wholesale retail trade nationally internationally certain products also sold drug manufacturers hospitals medical profession three wholesalers accounted approximately net sales restated sales two wholesalers accounted net sales restated sales one wholesaler accounted net sales restated included earnings income taxes segment cost capital charge offset cost capital charge included corporateother corporateother also includes interest expense interest income legal settlements restructuring charges gain sales assets certain administrative expenses allocations segments sales selected products product categories business segment follows year ended december restated restated restated dollars millions pharmaceuticals pravachol glucophage oncology therapeutics network plavix taxol paraplatin zerit avapro monopril serzone buspar nutritionals enfamil healthcareostomy earnings minority interest income taxes net sales restated restated restated restated restated restated business segment dollars millions pharmaceuticals nutritionals healthcare total segment corporateother net earnings minority interest income taxes included earnings minority interest income taxes cost capital charge offset cost capital charge included corporateother addition corporateother principally consists interest income interest expense certain administrative expenses allocations business segments certain corporate programs corporateother also includes gain sale businessesproduct lines million million million respectively provision restructuring items million million respectively pharmaceuticals segment includes charge acquired inprocess research development million million million respectively corporateother assets consist cash cash equivalents time deposits marketable securities goodwill certain assets year end assets restated restated dollars millions pharmaceuticals nutritionals healthcare identifiable segment assets corporateother total assets depreciation capital expenditures restated restated restated dollars millions pharmaceuticals nutritional healthcare business segment total corporateother total capital expenditures depreciation expense consolidated statement cash flows includes capital expenditures related discontinued operations million million million respectively million million million depreciation expense related discontinued operations respectively geographic areas net sales yearend assets restated restated restated restated restated dollars millions united states europe mideast africa western hemisphere pacific total bristolmyers squibb company notes restated consolidated financial statements note leases minimum rental commitments noncancelable operating leases primarily real estate effect december dollars millions years ending december later years total minimum payments less total minimum sublease rentals net minimum rental commitments operating lease rental expense net sublease rental income million million million million million million note retirement plans company certain subsidiaries defined benefit pension plans defined contribution plans regular fulltime employees principal pension plan bristolmyers squibb retirement income plan company 's funding policy contribute amounts provide current service fund past service liability plan benefits based primarily years credited service participant 's compensation plan assets consist principally equity fixedincome securities company domestic curtailmentsettlement loss approximately million resulting reductions employment levels primarily connection restructuring activities clairol divestiture cost company 's defined benefit plans included following components year ended december dollars millions service cost benefits earned year interest cost projected benefit obligation expected earnings plan assets net amortization deferral net pension expense curtailments settlements total pension expense weightedaverage actuarial assumptions company 's pension plans follows december discount rate compensation increase longterm rate return changes projected benefit obligation plan assets december dollars millions benefit obligation beginning year service cost benefits earned year interest cost projected benefit obligation curtailments settlements transfer dupont actuarial gains losses benefits paid benefit obligation end year fair value plan assets beginning year actual earnings plan assets employer contribution settlements transfer dupont benefits paid fair value plan assets end year plan assets excess less projected benefit obligation unamortized net obligation assets adoption unrecognized prior service cost unrecognized net gains losses net amount recognized amounts recognized consolidated balance sheet consist prepaid benefit cost accrued benefit liability asset net amount recognized projected benefit obligation accumulated benefit obligation fair value plan assets pension plans accumulated benefit obligations excess plan assets million million million respectively december million million million respectively december million million million respectively december attributable primarily unfunded benefit equalization plan december dupont pharmaceuticals company us pension plan company recognized minimum pension liability approximately million million december respectively principal defined contribution plan bristolmyers squibb savings investment program company 's contribution based employee contributions level company match company contributions plan million million million additional information company 's retirement plans see item management 's discussion analysis financial condition results operations note postretirement benefit plans pensions company provides comprehensive medical group life benefits substantially us retirees elect participate company 's comprehensive medical group life plans medical plan contributory contributions adjusted periodically vary date retirement original retiring company life insurance plan noncontributory plan assets consist principally equity securities fixedincome securities cost company 's postretirement benefit plans included following components year ended december dollars millions service costbenefits earned year interest cost accumulated postretirement benefit obligation expected earnings plan assets net amortization deferral curtailments net postretirement benefit expense weightedaverage actuarial assumptions company 's postretirement benefit plans follows december dollars millions discount rate longterm rate return changes benefit obligation plan assets year ended december dollars millions benefit obligation beginning year service cost benefits earned year interest cost accumulated postretirement benefit obligation plan participants ' contributions plan amendments actuarial gains losses curtailments benefits paid benefit obligation end year december dollars millions fair value plan assets beginning year actual earnings plan assets employer contribution plan participants ' contributions benefits paid fair value plan assets end year accumulated postretirement benefit obligation excess plan assets unrecognized prior service cost unrecognized net gains losses accrued postretirement benefit expense reported curtailments relate company 's restructuring divestiture activities measurement purposes annual rate increase per capita cost covered health care benefits participants assumed rate assumed decrease gradually remain level thereafter onepercentagepoint change assumed health care cost trend rates would following effects percentage percentage point increase point decrease dollars millions effect aggregate service interest cost components net postretirement benefit expense effect accumulated postretirement benefit obligation bristolmyers squibb company notes restated consolidated financial statements note litigation matters various lawsuits claims proceedings pending company certain subsidiaries accordance sfas accounting contingencies company records accruals contingencies probable liability incurred amount loss reasonably estimated significant litigation matters described taxol litigation company filed several lawsuits asserting number generic drug companies infringed patents covering methods administering paclitaxel filed abbreviated new drug applications seeking regulatory approval sell paclitaxel actions consolidated discovery us district court district new jersey district court company assert monetary claim defendants sought prevent defendants marketing paclitaxel manner violates patents defendants asserted infringe company 's patents patents invalid unenforceable early district court invalidated claims company 's patents issue april us court appeals federal circuit affirmed district court 's summary judgment invalidity two claims patents issue two claims relate lowdose threehour administration paclitaxel patient given specified regimen premedicants administration paclitaxel appellate court remanded two claims district court proceedings company filed additional patent infringement suit another company seeking market generic paclitaxel september one defendants received final approval us food drug administration fda abbreviated new drug application paclitaxel marketing product fda since announced additional final approvals sales additional generic products begun defendants asserted counterclaims seeking damages alleged antitrust unfair competition violations company believed patents valid filed suits counterclaims asserted believed without merit lawsuits defendants asserted counterclaims settled defendants agreeing drop claims relating paclitaxel company granting licenses certain paclitaxel patent rights since filing initial patent infringement suits six private actions filed parties alleging antitrust consumer protection similar claims relating company 's actions obtain enforce patent rights plaintiffs seek declaratory judgment damages including treble andor punitive damages allowed disgorgement injunctive relief june group state attorneys general district columbia puerto rico virgin islands brought similar claims september federal trade commission ftc initiated investigation relating paclitaxel january company announced reached agreements principle would settle substantially antitrust litigation surrounding taxol amount taxol antitrust settlements expected million amount accrued third quarter certain important terms conditions settlements remain finalized certain settlements require court approval final approval state attorneys general taxol litigation contingent upon agreements relating terms injunctive relief among provisions remaining negotiated terms incorporating certain claimants including number health insurers existing settlement framework company discussions number insurers whether ultimately join proposed settlement predicted certainty time company also reached agreement ftc staff terms consent order would resolve ftc 's investigation proposed consent order subject review approval ftc commissioners respect abovementioned proposed settlements possible time reasonably assess final outcome lawsuits reasonably estimate possible loss range loss respect lawsuits proposed settlements become final resolve taxolrelated antitrust consumer protection similar claims company prevail final nonappealable determinations ensuing litigation impact could material buspar litigation november company obtained patent us patent ' patent relating method using buspar buspirone company timely submitted information relating ' patent fda listing fda publication commonly known orange book fda thereafter listed patent orange book delisting patent suits genericdrug manufacturers sued fda company compel delisting ' patent orange book although one district court declined order delisting ' patent another ordered company cause delisting patent orange book company complied court 's order appealed decision united states court appeals federal circuit appellate court reversed district court ordered delisting concurrently company sought enforce ' patent actions two generic drug manufacturers antitrust suits following delisting ' patent orange book number purchasers buspirone several generic drug makers filed lawsuits company alleging improperly triggered statutory marketing exclusivity plaintiffs claimed violation antitrust consumer protection similar laws attorneys general states puerto rico also filed suit company parallel allegations plaintiffs amended allegations include charges agreement company generic company improperly blocked entry generic buspirone market plaintiffs seek declaratory judgment damages including treble andor punitive damages allowed disgorgement injunctive relief multidistrict litigation mdl proceedings judicial panel mdl granted company 's motions patent antitrust cases consolidated single forum court buspirone litigations pending issued two opinions dated february first opinion court found ' patent cover uses buspirone therefore infringed second opinion court denied company 's motion dismiss federal antitrust various state law claims second opinion allows claims company proceed except federal antitrust claims damagesaccrued four years filing complaints government investigations ftc number state attorneys general initiated investigations concerning matters alleged antitrust suits discussed company cooperated investigations number attorneys general filed action company noted proposed settlements january company announced reached agreements principle would settle substantially antitrust litigation surrounding buspar amount buspar settlements expected million million accrued fourth quarter million accrued first quarter million accrued third quarter written settlement agreements number parties signed certain settlements require court approval number health insurers agreed proposed settlement framework whether cases ultimately settled predicted certainty time company also reached agreement ftc staff terms consent order would resolve ftc 's investigation proposed consent order subject review approval ftc commissioners respect abovementioned proposed settlements buspar antitrust litigation possible time reasonably assess final outcome lawsuits reasonably estimate possible loss range loss respect lawsuits proposed settlements become final resolve busparrelated antitrust consumer protection similar claims company prevail final nonappealable determinations ensuing litigation impact could material vanlev litigation april may june company former chairman board chief executive officer charles heimbold jr former chief scientific officer peter ringrose phd named defendants number class action lawsuits alleging violations federal securities laws regulations actions consolidated one action us district court district new jersey plaintiff claims defendants disseminated materially false misleading statements failed disclose material information concerning safety efficacy commercial viability product vanlev period november april may plaintiff submitted amended complaint adding allegations company present chairman board chief executive officer peter r dolan former chairman board chief executive officer charles heimbold jr former chief scientific officer peter ringrose phd disseminated materially false misleading statements andor failed disclose material information concerning safety efficacy commercial viability vanlev period april march number related class actions making essentially allegations also filed us district court southern district new york actions transferred us district court district new jersey plaintiff purports seek compensatory damages costs expenses behalf shareholders possible time reasonably assess final outcome litigation reasonably estimate possible loss range loss respect litigation company prevail final nonappealable determinations litigation impact could material plavix litigation company part owner entity plaintiff two pending patent infringement lawsuits united states district court southern district new york entitled sanofisynthelabo sanofi synthelabo inc bristolmyers squibb sanofi pharmaceuticals holding partnership v apotex inc apotex corp cv rws sanofisynthelabo sanofisynthelabo inc bristolmyers squibb sanofi pharmaceuticals holding partnership v dr reddy 's laboratories ltd dr reddy 's laboratories inc cv rws suits based us patent discloses claims among things hydrogen sulfate salt clopidogrel marketed plavix us patent discloses claims among things use clopidogrel prevent secondary ischemic event plaintiffs ' infringement position based defendants ' filing abbreviated new drug applications fda seeking approval sell generic clopidogrel prior expiration patents suit possible time reasonably assess final outcome lawsuits reasonably estimate possible loss range loss respect lawsuits patent protection plavix lost impact company 's operations could material securities matters period march may company number current former officers named defendants number securities class action lawsuits alleging violations federal securities laws regulations plaintiffs variously alleged defendants disseminated materially false misleading statements failed disclose material information concerning three different matters safety efficacy commercial viability vanlev discussed company 's sales incentives certain wholesalers inventory levels wholesalers company 's investment relations imclone systems incorporated imclone imclone 's product erbitux discussed allegations concerning vanlev transferred us district court district new jersey consolidated action pending remaining actions consolidated pending us district court southern district new york allegations remaining actions cover period january april plaintiffs seek compensatory damages costs expenses october number company 's officers directors former directors named defendants shareholder derivative suit pending us district court southern district new york company nominal defendant suit alleges among things violations federal securities laws breaches contract fiduciary duty connection company 's sales incentives certain wholesalers inventory levels wholesalers investment imclone imclone 's product erbitux two similar actions pending new york state court plaintiffs seek damages costs attorneys ' fees april sec initiated inquiry wholesaler inventory issues referenced became formal investigation august december investigation expanded include certain accounting issues including issues related establishment reserves accounting forcertain asset sales october united states attorney 's office district new jersey announced investigation wholesaler inventory issues referenced since expanded cover subject matter sec investigation company cooperating investigations possible time reasonably assess final outcome litigations investigations reasonably estimate possible loss range loss respect litigations investigations company producing documents actively cooperating investigations investigations could result assertion criminal andor civil claims company prevail final nonappealable determinations litigations investigations impact could material erisa litigation december first quarter company others named defendants number class actions brought federal employee retirement income security act erisa cases pending us district courts southern district new york district new jersey plaintiffs allege defendants breached various fiduciary duties imposed erisa owed participants bristolmyers squibb company savings investment program program including duty disseminate material information concerning safety data company 's product vanlev company 's sales incentives certain wholesalers inventory levels wholesalers company 's investment relations imclone imclone 's product erbitux connection allegations plaintiffs assert defendants breached fiduciary duties diversify program assets monitor investment alternatives avoid conflicts interest remedy alleged fiduciary breaches cofiduciaries case pending district new jersey plaintiffs additionally allege violation defendants duty disseminate material information concerning alleged anticompetitive activities related company 's products buspar taxol pravachol plaintiffs seek recover losses caused defendants ' alleged violations erisa attorneys ' fees possible time reasonably assess final outcome matters reasonably estimate possible loss range loss respect lawsuits company prevail final nonappealable determinations matters impact could material average wholesale pricing litigation company together number pharmaceutical manufacturers defendant series state federal actions private plaintiffs brought purported class actions complaints filed attorneys general two states one county alleging manufacturers ' reporting prices certain products resulted false overstated average wholesale price awp turn improperly inflated reimbursement paid medicare beneficiaries insurers state medicaid programs medical plans others health care providers prescribed administered products federal cases many state cases including attorney general cases removed federal courts consolidated pretrial purposes transferred united states district court district massachusetts pharmaceutical industry average wholesale price litigation awp multidistrict litigation september several private plaintiffs awp multidistrict litigation filed master consolidated complaint master complaint superseded complaints preconsolidated constituent cases master complaint asserts claims federal rico statute state consumer protection fair trade statutes company defendants moved dismiss master complaint motions heard january nevada montana attorneys general moved respective cases remanded state court argument motion scheduled march company also defendant related state court proceedings new york new jersey california arizona tennessee one federal court proceeding new york commenced county suffolk new york new jersey state court proceedings currently stayed company defendants removed intend remove state court cases federal court seek transferred awp multidistrict litigation company anticipates county suffolk case also transferred plaintiffs seek damages well injunctive relief aimed manufacturer price reporting practices cases preliminary stage company unable assess outcome possible effect business profitability reasonably estimate possible loss range loss respect cases company together number pharmaceutical manufacturers also received subpoenas document requests various government agencies seeking records relating pricing marketing practices drugs covered medicare andor medicaid requests records come united states attorney 's office district massachusetts office inspector general department health human services conjunction civil division department justice several states company producing documents actively cooperating investigations could result assertion criminal andor civil claims company unable assess outcome reasonably estimate possible loss range loss respect investigations could include imposition fines penalties administrative remedies breast implant litigation company together subsidiary medical engineering corporation mec certain companies remains defendant number claims lawsuits alleging damages personal injuries various types resulting polyurethanecovered breast implants smoothwalled breast implants formerly manufactured mec related company vast majority claims company direct lawsuits resolved settlements trial likewise claims potential claims company registered nationwide class action settlement approved federal district court birmingham alabama revised settlement resolved revised settlement company established accruals respect breast implant product liability litigation company believes possible loss addition amounts accrued material note selected quarterly financial data unauditedfor description restatement items effect annual periods also affect unaudited quarterly data see note restatement previously issued financial statements restated consolidated financial statements first quarter second quarter third quarter previously previously previously reported restated reported restated reported restated dollars millions except per share data net sales gross margin net earnings continuing operations discontinued operations net net earnings earnings per common share basic earnings continuing operations discontinued operations net net earnings diluted earnings continuing operations discontinued operations net net earnings net sales gross margin net earnings continuing operations discontinued operations net net earnings earnings per common share basic earnings continuing operations discontinued operations net net earnings diluted earnings continuing operations discontinued operations net net earnings fourth quarter year previously previously reported restated reported restated dollars millions except per share data net sales gross margin net earnings continuing operations discontinued operations net net earnings earnings per common sharebasic earnings continuing operations discontinued operations net net earnings diluted earnings continuing operations discontinued operations net net earnings net sales gross margin net earnings continuing operations discontinued operations net net earnings earnings per common share basic earnings continuing operations discontinued operations net net earnings diluted earnings continuing operations discontinued operations net net earnings fourth quarter includes sales dupont million includes pretax gain sales businessesproduct lines million first quarter million second quarter million third quarter million fourth quarter first quarter third quarter fourth quarter also include pretax charges acquired inprocess research development million million million respectively second quarter third quarter fourth quarter include million reversals prior restructuring liabilities restructuring charges million million respectively addition million costs related dupont acquisition included fourth quarter first quarter results included gain sale business million provision restructuring items million second quarter results included gain sale business million provision restructuring items million third quarter results included provision restructuring items million fourth quarter results included gain sale business million million taxes first quarter results included pretax provision restructuring million million taxes third quarter results included pretax gain sale business million million taxes pretax provision restructuring million million taxes common equivalent shares excluded computation diluted loss per share fourth quarter effect would antidilutive report independent accountants board directors stockholders bristolmyers squibb company opinion restated consolidated financial statements listed index appearing item present fairly material respects restated financial position bristolmyers squibb company subsidiaries december results operations cash flows restated three years period ended december conformity accounting principles generally accepted united states america addition opinion restated financial statement schedule listed index appearing item presents fairly material respects information set forth therein read conjunction related consolidated financial statements financial statements financial statement schedule responsibility company 's management responsibility express opinion financial statements financial statement schedule based audits conducted audits statements accordance auditing standards generally accepted united states america require plan perform audit obtain reasonable assurance whether financial statements free materialmisstatement audit includes examining test basis evidence supporting amounts disclosures financial statements assessing accounting principles used significant estimates made management evaluating overall financial statement presentation believe audits provide reasonable basis opinion described note restatement previously issued financial statements company restated previously issued financial statements described note accounting policies company changed method accounting business combinations goodwill transactions consummated subsequent june pricewaterhousecoopers llp pricewaterhousecoopers llp new york new york march item changes disagreements accountants accounting financial disclosure none part iv item